| Entries |
| Document | Title | Date |
|---|
| 20080199491 | Sustained Release Vaccine Composition - A non-liquid vaccine composition including one or more antigen component(s); a pharmaceutically acceptable non-liquid adjuvant therefor; and optionally a non-liquid vaccine protection agent. | 08-21-2008 |
| 20080213306 | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines - The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE. | 09-04-2008 |
| 20080220016 | Method of Treating and Preventing Infectious Diseases via Creation of a Modified Viral Particle with Immunogenic Properties - The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious organism, thereby reducing the infectivity of the infectious organism. The present invention uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact, resulting in a modified viral particle. The present invention also provides an autologous vaccine composition, comprising a lipid-containing infectious organism, treated with solvents to reduce the lipid content of the infectious organism, combined with a pharmaceutically acceptable carrier. The vaccine composition is administered to an animal or a human to provide protection against the lipid-containing infectious organism. The present invention further provides a simple, inexpensive and easy to use kit for delipidating fluids and for delipidation of lipid-containing organisms in a fluid. | 09-11-2008 |
| 20080220017 | Method of Treating and Preventing Infectious Diseases via Creation of a Modified Viral Particle with Immunogenic Properties - The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious organism, thereby reducing the infectivity of the infectious organism. The present invention uses optimal solvent systems such that the lipid envelope around the viral particle is dissolved while the viral particle remains intact, resulting in a modified viral particle. The present invention also provides an autologous vaccine composition, comprising a lipid-containing infectious organism, treated with solvents to reduce the lipid content of the infectious organism, combined with a pharmaceutically acceptable carrier. The vaccine composition is administered to an animal or a human to provide protection against the lipid-containing infectious organism. The present invention further provides a simple, inexpensive and easy to use kit for delipidating fluids and for delipidation of lipid-containing organisms in a fluid. | 09-11-2008 |
| 20080226672 | Adjuvant Systems and Vaccines - An adjuvant composition comprising monophosphoryl lipid A or a derivative of monophposphoryl lipid A adsorbed onto an aluminium salt particle. | 09-18-2008 |
| 20080226673 | SUBUNIT VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTION - The present invention relates generally to methods of treating or preventing RSV infections, and more specifically, to compositions, and the use thereof, comprising one or more RSV G protein immunogen or fragment thereof capable of eliciting protective immunity without eliciting an immunopathological response or eliciting a reduced immunopathological response. | 09-18-2008 |
| 20080233147 | Circovirus sequences associated with piglet weight loss disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 09-25-2008 |
| 20080241185 | IMPRINTED POLYMERIC MATERIALS FOR BINDING VARIOUS TARGETS SUCH AS VIRUSES - Imprinted polymeric materials that selectively bind to a template article. Various types of template articles may be targeted by the imprinted polymeric materials, including microorganisms (e.g., viruses or bacteria) or biologic macromolecules (e.g., proteins or DNA). The imprinted polymeric material may be formed by template-directed synthesis using monomer units that interact with the template article. The monomer units are used to form a polymer matrix around the template article. Subsequently, the template article is removed from the polymer matrix. Also disclosed are imprinted polymeric materials comprising a cross-linked polymer matrix, which comprises a polyampholyte polymer. The polymer matrix has a binding cavity capable of selectively binding to a template article. Also disclosed are various uses for such imprinted polymeric materials. | 10-02-2008 |
| 20080248061 | Pcv-2 Vaccine - The present invention relates to a vaccine against porcine circovirus type 2 (PCV-)2 and a method for the manufacture of such a vaccine, for protecting piglets against PCV-2 infection. | 10-09-2008 |
| 20080248062 | Papillomavirus vaccine compositions - The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection. | 10-09-2008 |
| 20080254064 | COMPOSITIONS AND METHODS FOR PRIMING MONOCYTIC DENDRITIC CELLS AND T CELLS FOR TH-1 RESPONSE - The present invention provides compositions and methods for inducing maturation of immature dendritic cells (DC) and for priming those cells for inducing a type 1 immune response. The present invention also provides dendritic cell populations useful for activating and for preparing T cells polarized towards production of type 1 cytokines and/or a type 1 response. Similarly, activated, polarized T cell populations, and methods of making the same are provided. | 10-16-2008 |
| 20080260779 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 10-23-2008 |
| 20080267994 | Induction of dendritic cell development with macrophage-colony stimulating factor (M-CSF) - A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor is provided. M-CSF induces DCs to differentiate into subtypes, for example plasmacytoid DCs and conventional DCs. Induction with M-CSF can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention. | 10-30-2008 |
| 20080267995 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 10-30-2008 |
| 20080274137 | DNA plasmids having improved expression and stability - The present invention relates to compositions and methods to improve expression of exogenous polypeptides, such as an antigen, epitope, immunogen, peptide or polypeptide of interest. More particularly, the present invention provides for DNA plasmids with increased expression and stability in compositions and methods useful for DNA vaccines. | 11-06-2008 |
| 20080274138 | Formulation of Sugar Solutions for Continuous Ultracentrifugation for Virus Purification - The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool. | 11-06-2008 |
| 20080279888 | Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof - The present invention provides genetically engineered cell lines, recombinant vectors, and vaccines. The present invention also provides methods for generating an in vitro system for | 11-13-2008 |
| 20080279889 | USE OF A PCV2 IMMUNOGENIC COMPOSITION FOR LESSENING CLINICAL SYMPTOMS IN PIGS - The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and/or multinucleated/giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections. | 11-13-2008 |
| 20080279890 | VIRAL ANTIGENS - The present invention relates to a vaccine composition comprising VLPs containing L1 proteins or functional L1 protein derivatives from HPV 16, HPV 18, HPV 31 and HPV 45 genotypes. | 11-13-2008 |
| 20080286304 | Modifying Leukocyte Function - Use of PREPS and/or L-particles for the manufacture of a medicament for modifying or regulating leukocyte function. | 11-20-2008 |
| 20080286305 | Antigen Transduced T Cells Used as a Delivery System for Antigens - A delivery system comprising a T cell comprising at least one antigen capable of loading antigen-presenting-cells with the antigen. | 11-20-2008 |
| 20080292657 | PRIMATE T-LYMPHOTROPIC VIRUSES - Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses. | 11-27-2008 |
| 20080305128 | TREATMENT OF PRDC IN PIGS - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs. | 12-11-2008 |
| 20080311152 | MODULATION OF DEVELOPMENTAL IMMUNE PROGRAMMING AND PROTECTION AGAINST CARDIOVASCULAR DISEASE, DIABETES, INFECTIOUS DISEASES, AND CANCER - Maternal adaptive immunity conveys temporary humoral immune protection to neonates. The disclosure demonstrates the influence of the in utero environment on adult atherosclerosis and provides evidence for persistent effects of maternal immunization on adult immune responses. The disclosure provides methods and compositions useful for immunization and more particularly for actively modulating the fetal programming of the immune system for the purpose of preventing or treating immune-modulated diseases. The disclosure also provides interventions to protect offspring and immunized subjects against insulin resistance. | 12-18-2008 |
| 20080317777 | Cdna Construct Of Salmonidae Alphavirus - The invention concerns recombinant DNA's comprising cDNA of genomic RNA of a Salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant DNA's are useful for obtaining expression vectors, producing recombinant Salmonidae alphavirus, and for obtaining vaccines. | 12-25-2008 |
| 20090004221 | Mutant Porcine Reproductive and Respiratory Syndrome Virus - The present invention provides a genetically modified PRRS virus which has been modified such that the conserved cysteine in the E protein has been deleted or changed to a non-cysteine residue and polynucleotides that encode it. Vaccines comprising the genetically modified virus and polynucleotides are also provided. | 01-01-2009 |
| 20090017062 | Methods and compounds to alter virus infection - The invention provides a method to identify an agent that alters parvovirus transduction of mammalian cells. Also provided is a method to enhance transgene expression in a mammalian cell, as well as a method to identify an agent that alters NADPH oxidase activity in parvovirus transduced mammalian cells. | 01-15-2009 |
| 20090017063 | EDIBLE VACCINE - The object of the present invention is to provide an edible vaccine which is effective for human papilloma virus (HPV) type 16 and available in large amounts inexpensively. An edible human papilloma virus vaccine obtained by culturing a transformant of an avirulent fission yeast host, wherein the transformant carries a gene encoding an antigenic protein of human papilloma virus introduced therein and accumulates the expressed antigenic protein in it. | 01-15-2009 |
| 20090022761 | Enhancement of Immune Response to Vaccine by Interferon Alpha - Exogenous cDNA capable of expressing interferon″ activity, exogenous interferon″ protein, inducers of endogenous interferon″ protein activity, inducers of endogenous interferon $ protein activity, inducers of endogenous interferon′ activity, or inducers of other immune-enhancing activity can be combined with a vaccine to enhance an immune response. Specifically disclosed are adjuvant and vaccine combinations where the adjuvant comprises a cDNA capable of expressing interferon″ activity, a complex comprising polyriboinosinic-polyribocytidilic acid, or a complex comprising polyriboinosinic-polyribocytidilic acid, poly-L-lysine, and carboxymethylcellulose and where the vaccine is a live vaccine virus derived from a virus causing porcine reproductive and respiratory syndrome disease. | 01-22-2009 |
| 20090028902 | Modified Viral Particles with Immunogenic Properties and Reduced Lipid Content Useful for Treating and Preventing Infectious Diseases - The present invention relates to a method for reducing the occurrence and severity of infectious diseases, especially infectious diseases in which lipid-containing infectious viral organisms are found in biological fluids, such as blood. The present invention employs solvents useful for extracting lipids from the lipid-containing infectious viral organism thereby creating modified viral particles with reduced infectivity and enhanced antigenicity. The present invention provides vaccine compositions, comprising these modified viral particles with reduced infectivity and enhanced antigenicity, optionally combined with a pharmaceutically acceptable carrier or an immunostimulant. The vaccine composition is administered to a patient to provide protection against the lipid-containing infectious viral organism. The vaccine compositions of the present invention include combination vaccines of modified viral particles obtained from one or more strains of a virus and/or one or more types of virus. | 01-29-2009 |
| 20090041803 | Dioscorea Extracts - An extract from a tuber of a | 02-12-2009 |
| 20090047306 | ADJUVANT COMPOSITIONS - An adjuvant composition comprises a Th1-activating alkaloid, optionally further comprising an auxiliary adjuvant selected from a type 2 adjuvant (e.g. alum and/or MF59), a type 1 adjuvant and/or a balanced adjuvant. Vaccines comprising the adjuvant composition include nucleic acid(s) which encode one or more antigenic protein(s); protein(s) or peptide(s); glycoprotein(s); polysaccharide(s) (e.g. carbohydrate(s)); fusion protein(s); lipid(s); glycolipid(s); peptide mimic(s) of polysaccharides carbohydrate(s) and a protein(s) in admixture; carbohydrate-protein conjugate(s); cells or extracts thereof; dead or attenuated cells or extracts thereof; tumour cells or extracts thereof; viral particles (e.g. attenuated viral particles or viral components); allergen(s) mixtures thereof. | 02-19-2009 |
| 20090053263 | Inhibitors of Enveloped Virus Infectivity - The present invention relates to treatment of infection by enveloped viruses through the use of papain-like cysteine protease inhibitors and kits thereof. Specifically, methods for treatment of filoviruses as well as other enveloped viruses such as Nipah, in particular using cathepsin inhibitors are described. | 02-26-2009 |
| 20090060946 | Activation of antigen-specific T cells by virus/antigen-treated dendritic cells - The present invention relates to a T cell activating agent containing dendritic cells (DC) treated with virus-treated antigen and/or dendritic cells treated separately with virus and antigen, which may be used as a vaccine to stimulate an immune response in a patient obtainable by the activation of antigen-specific T cells (TC) in vivo, to a composition containing activated TC which are activated by the T cell activating agent in vitro, to a pharmaceutical composition containing the T cell activating agent and/or the composition as well as to methods for their production. | 03-05-2009 |
| 20090081251 | Production of Viral Vaccines in Suspension on Avian Embryonic Derived Stem Cell Lines - The present invention relates to the development and manufacturing of viral vaccines, particularly the industrial production of viral vectors and vaccines, and more particularly the use of avian embryonic stem cells, preferably the EBx cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses; the invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals. | 03-26-2009 |
| 20090087452 | METHODS AND APPARATUS FOR THE PRODUCTION OF VIRAL VACCINES - A viral vaccine in the dried state is described. Methods for drying viral vaccine in the liquid state into viral vaccine in the dried state are presented. The methods may include introducing the viral vaccine in the liquid state into a gas stream and recovering viral vaccine in the dried state from the gas stream. | 04-02-2009 |
| 20090092637 | Medicaments and methods to treat autoimmune disease and cancer - The present invention relates to methods and formulations for GAD-vaccination to evoke a systemic effect rather that a GAD-specific effect. The present invention may therefore be used in the treatment of disease in humans not bearing on a GAD-specific effect. The invention includes a method to treat an autoimmune disease or disorder by administering at least one sequestered autoantigen in a prime and boost regimen for sensitization purposes followed by a boost for treatment purposes. This may be done upon diagnosis. Examples of sequestered autoantigens include: GAD65, GAD67, Pro-Insulin, Basic Myelin Protein, MOG and Chondrotoin II. | 04-09-2009 |
| 20090092638 | POLYNUCLEOTIDES ALLOWING THE EXPRESSION AND SECRETION OF RECOMBINANT PSEUDO-VIRUS CONTAINING FOREIGN EPITOPES, THEIR PRODUCTION, AND USE - This invention provides a new approach to the design of a virus with a defective replication cycle, which can be rescued by wild type virus co-infection, and which expresses foreign antigenic epitopes that contribute to the elimination of virus infected cells and then to viral clearance. The vector of the invention, by expression of epitopes derived from common pathogens, by-passes existing tolerance of virus specific T cell responses. The vector will only replicate in virus infected cells. | 04-09-2009 |
| 20090098158 | REDUCTION OF CONCOMITANT INFECTIONS IN PIGS BY THE USE OF PCV2 ANTIGEN - The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. | 04-16-2009 |
| 20090098159 | Feline Cell Capable of Being Cultured Without Animal-Derived Protein, and Method for producing virus and method for producing vaccine using thereof - The present invention provides a cell strain which is derived from an fcwf-4 cell that is a cell derived from a feline whole fetus and which is capable of being cultured without animal-derived proteins, a method for producing the cell strain, and a method for producing a virus by using the cell. An inexpensive and safe feline vaccine can be produced according to the present invention. | 04-16-2009 |
| 20090104227 | VACCINE COMPOSITION FOR THE PREVENTION OF CMV INFECTION - The invention relates to a method for preventing HCMV infection in HCMV seronegative human subjects and for preventing HCMV congenital infection in newborns, which method comprises administering an effective amount of a vaccine composition containing the gB antigen of HCMV in an O/W emulsion to the seronegative human subjects. | 04-23-2009 |
| 20090117153 | Disulfide Trap MHC Class I Molecules and Uses Therefor - A disulfide trap, comprising an antigen peptide covalently attached to an MHC class I heavy chain molecule by a disulfide bond extending between two cysteines, is disclosed. In some configurations, a disulfide trap, such as a disulfide trap single chain trimer (dtSCT), can comprise a single contiguous polypeptide chain. Upon synthesis in a cell, a disulfide trap oxidizes properly in the ER, and can be recognized by T cells. In some configurations, a peptide moiety of a disulfide trap is not displaced by high-affinity competitor peptides, even if the peptide binds the heavy chain relatively weakly. In various configurations, a disulfide trap can be used for vaccination, to elicit CD8 T cells, and in multivalent MHC/peptide reagents for the enumeration and tracking of T cells. Also disclosed are nucleic acids comprising a sequence encoding a disulfide trap. Such nucleic acids, which can be DNA vectors, can be used as vaccines. | 05-07-2009 |
| 20090123493 | Composition Comprising a Colloidal Synthetic Bioresorbable Vector and a Viral Vector - The invention relates to pharmaceutical compositions containing a colloidal synthetic bioresorbable vector which comprises at least one type of proteinic substance, to a viral vector corresponding to at least one type of proteinic substance of the synthetic vector and to a method for the prophylactic, therapeutic and diagnosis use thereof. | 05-14-2009 |
| 20090130143 | N PROTEIN MUTANTS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS - The present invention provides a genetically modified PRRS virus, methods to make it and related polypeptides, polynucleotides and various components. Vaccines comprising the genetically modified virus and polynucleotides are also provided. | 05-21-2009 |
| 20090142372 | Therapeutic composition for use in the prevention and treatment of bone metastases - The invention is relates to drugs on the basis of antibodies against non-cellular bone matrix proteins, especially BSP, for use in the prevention and treatment of bone metastases. According to the invention, the antibodies are induced in the patient by recombinantly expressing antigenic determinants of bone matrix proteins in | 06-04-2009 |
| 20090148474 | PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME ISOLATES AND METHODS OF USE - A method of predicting the virulence of a new or uncharacterized PRRS virus isolate is provided wherein the isolate is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and/or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and/or viremia magnitude of a PRRS virus isolate of known virulence, as a measure of the virulence of the new or uncharacterized isolate. Additionally, a method of selecting an isolate for inclusion in an immunogenic composition based on the predicted virulence is also provided, together with compositions incorporating attenuated forms of viruses predicted to be virulent. | 06-11-2009 |
| 20090148475 | IDENTIFICATION OF PROTECTIVE ANTIGENIC DETERMINANTS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF - The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV. | 06-11-2009 |
| 20090155306 | Pamps, pathogen associated molecular patterns - A method for identifying a polypeptide which acts as an adjuvant in a host organism. The invention further provides adjuvant compositions comprising said polypeptides and optionally further comprising an antigen. | 06-18-2009 |
| 20090155307 | IMMUNOSTIMULATORY NUCLEIC ACID OIL-IN-WATER FORMULATIONS AND RELATED METHODS OF USE - The invention involves methods and compositions of an immunostimulatory nucleic acid in oil-in-water emulsions for topical delivery. The compositions can be used to stimulate immune responses, particularly useful in the prevention and/or treatment of infectious disease and cancer. | 06-18-2009 |
| 20090181051 | N-linked glycosylation alteration in E1 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine - E1, along with Erns and E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). Our previous studies indicated that glycosylation status of either E2 or Erns strongly influence viral virulence in swine. Here, we have investigated the role of E1 glycosylation of highly virulent CSFV strain Brescia during infection in the natural host. The three putative glycosylation sites in E1 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E1 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all three putative glycosylation sites in E1. Single mutations of each of the E1 glycosylation sites showed that CSFV amino acid N594 (E1.N3 virus), as well the combined mutation of N500 and N513 (E1.N1N2 virus) resulted in BICv attenuation. Infection of either E1.N1N2 or E1.N3 viruses were able to efficiently protected swine from challenge with virulent BICv at 3 and 28 days post-infection. These results, along with those demonstrating the role of glycosylation of E | 07-16-2009 |
| 20090202589 | FERMENTER SYSTEM FOR BIOTECHNICAL PROCESSES - A fermenter for use in biotechnical processes in particular for culturing cells is disclosed. The object, to provide a fermenter vessel ( | 08-13-2009 |
| 20090208528 | Empty capsids (vlps(-vp4)) of the infectious bursal disease virus (ibdv), obtainment process and applications - The empty capsids of the infectious bursal disease virus (IBDV), VLP(−VP4), are characterized in that they are constituted only by assembly of IBDV pVP2 proteins and IBDV VP3 proteins. Said capsids have immunogenic activity and can be used in the manufacture of vaccines for protecting animals from the infection caused by IBDV, as well as in the manufacture of gene therapy vectors. | 08-20-2009 |
| 20090208529 | Recombinant Novirhabdoviruses and Uses Thereof - The invention relates to recombinant novirhabdoviruses having at least one sequence encoding a polypeptide of interest added to their genome. Said recombinant novirhabdoviruses are useful as gene vectors, for producing recombinant proteins, or for producing vaccines for fish or for higher vertebrates. | 08-20-2009 |
| 20090214589 | Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine - Use of a recombinant lentiviral vector comprising a polynucleotide fragment encoding at least one protein of a virus of the family Flaviviridae or an immunogenic peptide of at least 8 amino acids of said protein, for preparing a pharmaceutical composition intended for the prevention and/or the treatment of a Flaviviridae infection in a sensitive species. | 08-27-2009 |
| 20090232841 | Optimzed vaccines to provide protection against ebola and other viruses - The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same. | 09-17-2009 |
| 20090232842 | HPV Vaccine Comprising Peptides From Host Cell Proteins - The present invention relates to a human papillomavirus (HPV) vaccine that comprises peptides from host cell proteins and more particularly, a vaccine that is directed against cancers that are associated with HPV infections, such as cervical cancer, head and neck cancer and skin cancers. The peptides comprise fragments of host cell proteins that have been targeted for degradation by HPV proteins, such as E6 and E7 and are presented on the surface of HPV infected cells in relatively large amounts. These peptides can be recognised by CTL and elicit an immune response, and are therefore ideal tumour-specific markers. The invention also relates to novel peptide: peptide complexes such as peptide/HLA complexes and their use in a tumour-specific vaccine. | 09-17-2009 |
| 20090238844 | Porcine reproductive and respiratory syndrome virus strains and compositions - This invention relates to two attenuated strains of porcine reproductive and respiratory syndrome virus (PRRSV) and immunogenic compositions comprising one or more strains of attenuated porcine reproductive and respiratory syndrome virus (PRRSV). | 09-24-2009 |
| 20090252761 | Papilloma virus vaccine - A method of providing papilloma virus like particles which may be used for diagnostic purposes or for incorporation in a vaccine for use in relation to infections caused by papilloma virus. The method includes an initial step of constructing one or more recombinant DNA molecules which each encode papilloma virus L1 protein or a combination of papilloma virus L1 protein and papilloma virus L2 protein followed by a further step of transfecting a suitable host cell with one or more of the recombinant DNA molecules so that virus like particles (VLPs) are produced within the cell after expression of the L1 or combination of L1 and L2 proteins. The VLPs are also claimed per se as well as vaccines incorporating the VLPs. | 10-08-2009 |
| 20090258034 | Method of Inducing Mucosal Immune Response to Antigen with Dioscorea Polysaccharides Adjuvant - A method for inducing mucosal immune responses in a subject in need thereof to an antigen includes administering to the subject a vaccine composition including the antigen and a | 10-15-2009 |
| 20090263420 | Virus-Like Particles As Vaccines For Paramyxovirus - The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines. | 10-22-2009 |
| 20090311287 | Novel flavivirus antigens - The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided. | 12-17-2009 |
| 20090317424 | Oral vaccines - This invention features a composition that includes a multiple-cell organism for use as food for an aquatic animal (e.g., a fish or a shrimp), and a single-cell organism fed to, and as a result, bioencapsulated by, the multiple-cell organism. The single-cell organism has been transformed to express a recombinant antigen that induces an immune response in the aquatic animal. | 12-24-2009 |
| 20100003278 | Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof - The present application describes improved an immunogenic compositions of virus vaccines wherein the virus vaccines comprise adjuvants selected from the group consisting of MCP-1, | 01-07-2010 |
| 20100015178 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE - The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives. | 01-21-2010 |
| 20100028380 | B CELL-BASED VACCINE LOADED WITH THE LIGAND OF NATURAL KILLER T CELL AND ANTIGEN - The present invention relates to a B cell-based vaccine loaded with the ligand of natural killer T cell and antigen for the prevention and treatment of disease, more precisely, an immunotherapeutic and prophylactic vaccine mediated by B cells loaded with α-galactosylceramide, a kind of glycolipid which can stimulate natural killer T cells. A vaccine composition of the present invention can be effectively used as an antitumor immunotherapeutic agent. B cells therein, which are easily obtainable compared with dendritic cells, not only induce a similar level of cytotoxic T lymphocyte response to that of the conventional dendritic cell-based vaccine but also have a prophylactic and therapeutic effect on solid tumor and metastatic tumor. | 02-04-2010 |
| 20100028381 | FORMULATION FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS - The present invention provides pharmaceutical compositions that include an IRM-PEG complex and an antigen, formulated together in a thermoresponsive gel. In another aspect, the present invention also provides a method of eliciting an antigen-specific immune response in a subject. Generally, the method includes administering to the subject a pharmaceutical composition comprising an IRM-PEG complex and an antigen, formulated together in a thermoresponsive gel, in an amount effective to generate an immune response in the subject against the antigen. In yet another aspect, the present invention also provides a method of treating a condition in a subject. Generally, the method includes administering to the subject a pharmaceutical composition comprising an IRM-PEG complex and an antigen, formulated together in a thermoresponsive gel, in an amount effective to ameliorate at least one symptom or clinical sign of the condition. | 02-04-2010 |
| 20100047273 | Coxsackie B virus and type 1 diabetes - Type 1 diabetes mellitus is characterized by loss of pancreatic insulin-producing beta cells, resulting in insulin deficiency. The usual cause of this beta cell loss is autoimmune destruction. Coxsackie virus has been detected in human pancreatic beta cells and causes insulitis. This non-destructive islet inflammation does not itself cause diabetes, but this disease will occur if viral infection is followed by a separate autoimmune response. The insulitis is mediated mainly by natural killer cells. Islets from coxsackie virus positive samples displayed reduced insulin secretion in response to glucose and other secretagogues. Virus extracted from positive islets was able to infect beta cells from human islets of non-diabetic donors, causing viral inclusions and signs of pyknosis. | 02-25-2010 |
| 20100047274 | INOCULATION OF RECOMBINANT VIRAL VECTORS FOR RAPID PRE-EXPOSURE PREVENTION AND POST-EXPOSURE PROTECTION AGAINST ALPHA-VIRUS-INDUCED ENCEPHALITIDES - This invention addresses how to rapidly prevent alphavirus-induced encephalitides before and after exposure to alphaviruses. The invention discloses a single dose administration of two types of recombinant viral vectors: one expressing interferon and another expressing the structural proteins of alphaviruses or a single dose administration of the recombinant viral vector co-expressing both interferon and the structural proteins of alphaviruses. This invention can be used to prevent humans from alphavirus-induced encephalitides in the event of a bioterrorism attack or biowarfare in which alphaviruses such as Venezuelan (VEEV), eastern (EEEV) and western (WEEV) equine encephalitis viruses are deliberately released to humans, a natural outbreak of alphaviruses, and an accidental exposure to alphaviruses in laboratory. | 02-25-2010 |
| 20100055128 | METHOD FOR THE PURIFICATION OF ALPHAVIRUS REPLICON PARTICLES - Methods of production and purification for viruses and virus-derived vectors, including those related to alphaviruses, are disclosed. in one aspect, methods of purification that subject alphavirus replicon particle preparations to one or more steps of chromatographic purification, such as using an ion exchange resin, are provided. Also disclosed are methods of characterizing alphavirus replicon particles and utilizing these materials for vaccines and gene-based therapeutics. | 03-04-2010 |
| 20100068225 | VACCINE FOR PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, A PREPARION METHOD AND USE THEREOF - Aspects of the present inventions discloses a Super-Virulent Variant Strain of Porcine Reproductive and Respiratory Syndrome Virus, characterized in that nucleotides 1594th-1680th are deleted in its Nsp2 gene. The present invention also discloses a Vaccine prepared with the Super-Virulent Variant Strain of the Virus for prevention of Porcine Reproductive and Respiratory Syndrome. The present invention may further discloses preparations, assay methods and/or the application of the Vaccine in preparing medicaments to resist Super-Virulent Variant Strain of Porcine Reproductive and Respiratory Syndrome Virus by immunizing pigs. | 03-18-2010 |
| 20100074919 | Circovirus sequences associated with piglet weight loss disease (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 03-25-2010 |
| 20100080824 | HUMAN VIRUS CAUSING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) AND USES THEREOF - The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences. | 04-01-2010 |
| 20100080825 | FILOVIRUS VECTORS AND NONINFECTIOUS FILOVIRUS-BASED PARTICLES - Cloned filovirus genomic cDNA and methods of using the cDNA are provided. Further provided are noninfectious lipid encapsulated filovirus-based particles. | 04-01-2010 |
| 20100080826 | PROCESS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, RHEUMATOID ARTHRITIS, TREMORS/PARKINSON'S DISEASE, MULTIPLE SCLEROSIS AND NON-VIRAL BASED CANCERS - The present invention provides a composition and method for treating diseases associated with demyelination of the nerves, such as ALS, RA, Tremors/Parkinson's Disease, and MS, and for treating non-viral based cancers. By administering measured doses of an immunity-provoking agent and a bacterial antigen activator, patients suffering from ALS, RA, MS, Tremors/Parkinson's Disease, and prostrate cancer realized immediate beneficial results with no side effects. | 04-01-2010 |
| 20100086565 | Vectors for expression of hml-2 polypeptides - A nucleic acid vector comprising: (i) a promoter; (ii) a sequence encoding a HML-2 polypeptide operably linked to said promoter; and (iii) a selectable marker. Preferred vectors comprise: (I) a eukaryotic promoter; (ii) a sequence encoding a HML-2 polypeptide downstream of and operably linked to said promoter, (iii) a prokaryotic selectable marker; (iv) a prokaryotic origin of replication; and (v) a eukaryotic transcription terminator downstream of and operably linked to said sequence encoding a HML-2 polypeptide. Vectors of the invention are particularly useful for expression of HML-2 polypeptides either in vitro (e.g. for later purification). Or in vivo (e.g. for nucleic acid immunization). They are well suited to nucleic acid immunization against prostrate tumors. A preferred HML-2 is PCAV, which is located in chromosome 22 at 20.428 megabases (22q11.2). | 04-08-2010 |
| 20100092512 | Methods for preventing and ameiliorating porcine respiratory and reproductive syndrome virus-associated disease by immunizing against porcine ttv infection - Compositions and methods for preventing and ameliorating Porcine respiratory and reproductive syndrome virus (PRRSV)-associated diseases in pigs by immunizing against Torque teno virus (TTV) are disclosed. Also described are methods of identifying compounds for the treatment and prevention of PRRSV-associated diseases. | 04-15-2010 |
| 20100098722 | Packaging of Immunostimulatory Substances Into Virus-Like Particles: Method of Preparation and Use - The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases. | 04-22-2010 |
| 20100129397 | EFFECTIVE METHOD OF TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS - The present invention relates to the use of porcine circovirus type 2 (PCV2) antigen and | 05-27-2010 |
| 20100129398 | Materials and Methods for Control of Porcine Reproductive and Respiratory Syndrome - Methods of reducing the severity of porcine reproductive and respiratory syndrome virus (PRRSV) infections, as well as, methods of preventing such infections are provided. The methods provide for the age-based innoculation of swine with PRRS antigen, preferably Ingelvac® ATP. | 05-27-2010 |
| 20100136050 | Extracellular Matrix Materials as Vaccine Adjuvants for Diseases Associated with Infectious Pathogens or Toxins - Disclosed are vaccines and vaccine adjuvants useful in the treatment and/or prevention of infection and diseases associated with infectious pathogens, such as tetanus, as well as diseases associated with biological toxins. Also provided are methods of preparing an adjuvant and the vaccine containing the adjuvant. Methods are also provided for vaccinating/immunizing an animal against infection and diseases associated with infectious pathogens, such as tetanus, and other diseases associated with biological toxins. Adjuvant materials are presented that are prepared from an extracellular matrix material. The adjuvants are demonstrated to enhance the immunogenicity of an infectious pathogen antigen or biological toxin antigen of interest, as well as to enhance the survival of an immunized animal. | 06-03-2010 |
| 20100136051 | N Protein Muants of Porcine Reproductive and Respiratory Syndrome Virus - The present invention provides a genetically modified PRRS virus, methods to make it and related polypeptides, polynucleotides and various components. Vaccines comprising the genetically modified virus and polynucleotides are also provided. | 06-03-2010 |
| 20100143404 | Thiophene derivatives for up-regulating HLA-DM activity - Compounds of formula (I), compositions, methods and kits are provided. The compounds and compositions may be particularly useful for modulating immunological responses. Formula (I) wherein, R | 06-10-2010 |
| 20100143405 | Immunotherapy of virus infection - The present invention relates to a method of treating or preventing a virus infection in a subject. In particular, it relates to the use of autologous dendritic cells that have been matured and loaded ex vivo with hepatitis C virus (HCV) antigens, to initiate a cellular immune response in HCV-positive patients, after autologous transfusion. | 06-10-2010 |
| 20100143406 | METHODS OF ENHANCING PROTEIN INCORPORATION INTO VIRUS LIKE PARTICLES - The present invention comprises a method of increasing glycoprotein incorporation on the surface of VLPs, comprising expressing a nucleic acid encoding a chimeric glycoprotein in a host cell, wherein said chimeric glycoprotein comprises the transmembrane domain of an influenza hemagglutinin protein. The invention also embodies specific VLPs comprising said chimeric glycoproteins and methods of inducing immunity in an animal utilizing said VLPs. | 06-10-2010 |
| 20100143407 | Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences - The present invention provides an isolated mammalian negative strand RNA virus, | 06-10-2010 |
| 20100143408 | PAPILLOMAVIRUS VACCINES - A nucleic acid molecule encoding at least one papillomavirus E2 polypeptide, or a vector, an infectious viral particle or a therapeutic composition thereof is formulated into a drug product useful for treating a patient suffering from a persistent papillomavirus infection caused by at least one papillomavirus; particular such vectors are nucleic acid molecules containing a first nucleotide sequence encoding a papillomavirus E1 polypeptide and a second nucleotide sequence encoding a papillomavirus E2 polypeptide wherein the 3′ portion of the first nucleotide which in the natural content is 100% identical to the 5′ portion of the second nucleotide is modified so as to exhibit a percentage of identity between said portions of at most 75%. | 06-10-2010 |
| 20100143409 | Generation of virus-like particles and use as panfilovirus vaccines - In this application are described filovirus-like particles for both Ebola and Marburg and their use as a diagnostic and therapeutic agent as well as a filovirus vaccine. Also described is the association of Ebola and Marburg with lipid rafts during assembly and budding, and the requirement of functional rafts for entry of filoviruses into cells. | 06-10-2010 |
| 20100150959 | PCV 2-Based Methods and Compositions for the Treatment of Pigs - The present invention relates to methods and compositions for vaccinating pigs against porcine circovirus associated diseases. | 06-17-2010 |
| 20100158941 | Compositions and Methods for Treating Microbial Infections - The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions. | 06-24-2010 |
| 20100172933 | Recombinant vectors based on the modified vaccinia ankara (mva) virus as vaccines against lieshmaniasis - The invention relates to recombinant vectors based on the Modified Vaccinia Ankara (MVA) virus as vaccines against leishmaniasis. The inventive vectors contain sequences encoding the LACK protein, which are preferably inserted into the hemagglutinin locus of the virus under the control of a promoter, which enables the expression of same throughout the infection cycle of the virus. The invention comprises stable, safe vectors which elicit a strong immune response that provides protection against leishmaniasis and which, as such, are particularly suitable for use in vaccination against said disease, especially in humans, s well as in the largest animal reservoir of said anthropozoonosis, i.e. dogs. | 07-08-2010 |
| 20100172934 | METHOD FOR PRODUCTION OF pH STABLE ENVELOPED VIRUSES - The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity. | 07-08-2010 |
| 20100172935 | Method for viral inoculation of the vestibular region of the nares - A method of inoculation of the vestibular region of the nares with a virus, provides the steps of: applying the virus exclusively to the anterior vestibular region of the nares; and avoiding penetration of the virus beyond the vestibular region during application. | 07-08-2010 |
| 20100172936 | CHIMERIC PAPILLOMAVIRUS-LIKE PARTICLES - The present invention provides a papillomavirus-like particle, characterized as having conformational epitopes, comprising a papillomavirus L1 product and a papillomavirus L2 fusion product; and related synthetic DNA molecules, host cells, methods and vaccines. | 07-08-2010 |
| 20100183665 | PROMOTERLESS CASSETTES FOR EXPRESSION OF ALPHA VIRUS STRUCTURAL PROTEINS - The present invention provides an isolated RNA molecule comprising: a) an alphavirus 5′ replication recognition sequence, wherein at least one initiation codon has been removed from the 5′ replication recognition sequence; b) a nucleotide sequence encoding an alphavirus structural protein; and c) an alphavirus 3′ replication recognition sequence, with the proviso that the RNA molecule does not contain a promoter that directs transcription of the nucleotide sequence of (b), and wherein the alphavirus 5′ and 3′ replication recognition sequences of (a) and (c) direct replication of the RNA molecule in the presence of alphavirus non-structural proteins. | 07-22-2010 |
| 20100183666 | METHODS OF REDUCING PAPILLOMAVIRUS INFECTION USING IMMUNOMODULATORY POLYNUCLEOTIDE SEQUENCES - The invention provides methods for the treatment of papillomavirus infections. A polynucleotide comprising an immunostimulatory sequence is administered to an individual who has been exposed to or infected by papillomavirus. The polynucleotide is not administered with papillomavirus antigen. Administration of the polynucleotide results in amelioration of symptoms of papillomavirus infection. | 07-22-2010 |
| 20100189742 | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines - The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B. | 07-29-2010 |
| 20100189743 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 07-29-2010 |
| 20100189744 | PAPILLOMAVIRUS VACCINE COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection. | 07-29-2010 |
| 20100196419 | ENHANCEMENT OF GLYCOPROTEIN INCORPORATION INTO VIRUS-LIKE PARTICLES - Embodiments of the present disclosure encompasses virus-like particles, methods of making virus-like particles, including expression vectors, wherein the virus-like particles may comprise enhanced levels of capsid-bound a chimeric HN-Env polypeptide compared to VLPs derived from unmodified HIV-env polypeptides. Embodiments of the virus-like particle may have Env-specific epitopes exposed on the outer surface thereof. In one embodiment, the Env-specific epitopes exposed on the outer surface of the virus-like particle may specifically bind with an anti-HIV-Env specific antibody. Embodiments of the disclosure further includes methods of generating an antibody specific to an epitope of an HIV-Env polypeptide, comprising delivering to an animal or a human an effective amount of a suspension of virus-like particles comprising a chimeric HIV-Eny polypeptide, thereby inducing the formation of an antibody specific to an epitope of an HIV-1 eny polypeptide. | 08-05-2010 |
| 20100203081 | VIRAL INHIBITORY NUCLEOTIDE SEQUENCES AND VACCINES - The invention relates to inhibitory nucleotide signal sequences or “INS” sequences in the genomes of lentiviruses. In particular the invention relates to the AGG motif present in all viral genomes. The AGG motif may have an inhibitory effect on a virus, for example by reducing the levels of, or maintaining low steady-state levels of, viral RNAs in host cells, and inducing and/or maintaining in viral latency. In one aspect, the invention provides vaccines that contain, or are produced from, viral nucleic acids in which the AGG sequences have been mutated. In another aspect, the invention provides methods and compositions for affecting the function of the AGG motif, and methods for identifying other INS sequences in viral genomes. | 08-12-2010 |
| 20100203082 | VIRUS-MODIFIED BACTERIA GHOSTS - The invention relates to virus-modified bacteria ghosts and the use thereof, for example, as carrier and targeting vehicles for active ingredients. | 08-12-2010 |
| 20100209452 | COMPOSITIONS COMPRISING AN ANTIGEN, AN AMPHIPATHIC COMPOUND AND A HYDROPHOBIC CARRIER, AND USES THEREOF - The present invention provides compositions comprising an antigen, an amphipathic compound, and a hydrophobic carrier and methods of using these compositions for inducing an antibody or cell-mediated response in a subject. | 08-19-2010 |
| 20100215693 | IMMUNOLOGICAL HERPES SIMPLEX VIRUS ANTIGENS AND METHODS FOR USE THEREOF - The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are antigens and/or their constituent epitopes confirmed to be recognized by T-cells derived from herpetic lesions or from uterine cervix. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection. | 08-26-2010 |
| 20100221283 | CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) - The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided. | 09-02-2010 |
| 20100233206 | Marek's Disease Virus Vaccine Compositions and Methods of Using Thereof - Marek's disease virus (MDV), the etiologic agent of Marek's disease, is a potent oncogenic herpesvirus. MDV is highly contagious and elicits a rapid onset of malignant T-cell lymphomas in chickens within weeks after infection. MDV codes for an oncoprotein, Meq, that shares resemblance with the Jun/Fos family of b-ZIP transcription factors. Earlier studies showed that Meq is responsible for development for T-cell lymphomas in chicken. In order to identify specific regions within the Meq gene, a series of recombinant MDV were generated in which a mutated gene was introduced in place of parental Meq gene. Various mutations were introduced at the phosphorylation sites, basic region, leucine zipper region and transactivation regions of the Meq gene. Several of these mutations have been shown to have an attenuated phenotype in chickens. In one embodiment, the present invention contemplates exploiting these mutations to develop MDV vaccines that are able to protect against challenge with highly virulent MDV strains. | 09-16-2010 |
| 20100239606 | Two-Step Temperature Profile for the Propagation of Viruses - The present invention provides a method for the production of a virus. The method includes providing a host cell that has been infected by the virus and cultivating the infected host cell at two different temperatures. The virus produced by the cultivation steps is subsequently collected. By using the dual temperature cultivation process, high titer and improved purity can be obtained. | 09-23-2010 |
| 20100239607 | COMPOSITIONS FOR INDUCING IMMUNE RESPONSES - The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imidazoquinoline, wherein said first antigen is encapsulated within, adsorbed or conjugated to, co-lyophilized or mixed with said first adjuvant, and a pharmaceutically acceptable excipient, wherein said composition elicits a cellular immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions, methods for producing a cytotoxic-T lymphocyte (CTL) response in a vertebrate subject, and methods of immunization. | 09-23-2010 |
| 20100247568 | NOVEL ADJUVANT - The present invention provides a vaccine adjuvant composition which is used in combination with an allergen vaccine, infection vaccine or tumor vaccine. The present invention specifically provides a vaccine adjuvant composition comprising hemozoin or β-hematin and being used in combination with an allergen vaccine, infection vaccine or tumor vaccine, and a vaccine composition comprising the vaccine adjuvant composition and an allergen vaccine, infection vaccine or tumor vaccine | 09-30-2010 |
| 20100255031 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 16 - The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer. | 10-07-2010 |
| 20100266630 | Recombinant MVA virus, and the use thereof - The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines. | 10-21-2010 |
| 20100266631 | Compositions and Methods for Generating an Immune Response Utilizing Alphavirus-Based Vector Systems - Compositions and methods are provided for Eukaryotic Layered Vector Initiation Systems and Alphavirus replicon particles for introducing heterologous sequences into cells for generating immune responses. | 10-21-2010 |
| 20100272749 | Optimized expression of HPV 58 L1 in yeast - Synthetic DNA molecules encoding the HPV58 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV58 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV58 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV58 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity and are also useful for treatment of existing HPV infections. | 10-28-2010 |
| 20100272750 | HPV POLYEPITOPE CONSTRUCTS AND USES THEREOF - The present invention is directed to HPV polyepitope construct and the use thereoffor the prevention and/or treatment of HPV infection. | 10-28-2010 |
| 20100272751 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 18 - The invention relates to a truncated L1 protein of the Human Papillomavirus Type 18, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer. | 10-28-2010 |
| 20100278858 | PROCESS FOR PREPARING ATTENUATED VIRAL STRAINS - Provided is a process for preparing attenuated viral strains, comprising to contact, at least one sulphated polymer and a virus susceptible to the inhibition of the polymer, via successive passages of the virus with increasing polymeric concentrations, where the amenable virus is characterized by the method of reducing viral plates and where the strain resulting from the attenuated virus has stable phenotypic and genotypic characteristics, different from that of the virus strain in wild state that generated thereto. The process comprises to contact the sulphated polymer(s) with the virus susceptible to the inhibition of the polymer via about 15 or more successive passages with increasing concentrations of the sulphated polymer(s). According to the inventive process, the concentration of the at least one sulphated polymer in the first passage should be less than the IC | 11-04-2010 |
| 20100278859 | DIAGNOSTIC TEST KITS - This invention provides kits, devices, and methods for the detection of antibodies that recognize one or more proteins and/or antigens from porcine reproductive and respiratory syndrome virus (PRRSV). The antibodies may be in a biological fluid of a PRRSV infected or at risk subject. The invention may be advantageously applied to both the diagnosis and prevention of PRRSV infection. | 11-04-2010 |
| 20100285058 | DNA VACCINE FOR TREATING OR PREVENTING CERVICAL CANCER COMPRISING A GENE ENCODING HPV PROTEIN - Disclosed herein is a DNA vaccine for treating cervical cancer including an E5 gene of human papillomavirus (HPV). Also, disclosed is a combination DNA vaccine for preventing and treating cervical cancer including a gene encoding HPV L1 and/or L2 along with the HPV E5 gene. | 11-11-2010 |
| 20100285059 | Cytomegalovirus Vaccines and Methods of Production - Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising CMV isolated from epithelial cells are also disclosed. | 11-11-2010 |
| 20100285060 | ALPHA THYMOSIN PEPTIDES AS VACCINE ENHANCERS - The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer duration of such antibody titers, thereby providing a greater protective effect. In another aspect, the invention allows for reducing a vaccine dose, such as an influenza vaccine dose, by administration of a thymosin peptide regimen. | 11-11-2010 |
| 20100291141 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 11 - The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections. | 11-18-2010 |
| 20100297171 | DEVELOPMENT OF A PREVENTIVE VACCINE FOR FILOVIRUS INFECTION IN PRIMATES - The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus. | 11-25-2010 |
| 20100297172 | REPLICATION-DEFECTIVE ARENAVIRUS VECTORS - The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases. | 11-25-2010 |
| 20100303857 | DEVELOPMENT OF A PREVENTIVE VACCINE FOR FILOVIRUS INFECTION IN PRIMATES - The present invention relates generally to viral vaccines and, more specifically, to filovirus vaccines and methods of eliciting an immune response against a filovirus or disease caused by infection with filovirus. | 12-02-2010 |
| 20100310600 | SELECTIVE AGONIST OF TOLL-LIKE RECEPTOR 3 - A mismatched double-stranded ribonucleic acid, which is an agonist for Toll-like receptor 3 (TLR3), is used in vitro or in vivo as an antimicrobial agent, antiproliferative agent, and/or immunostimulant. Poly(l:C | 12-09-2010 |
| 20100316671 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES - The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals. | 12-16-2010 |
| 20100322965 | VIRAL VACCINE VECTORS - The present invention relates to a hybrid-viral vector system, in particular, but not exclusively, to a hybrid-viral vector system that can be used as a vaccine vector. | 12-23-2010 |
| 20100322966 | Method for allogeneic cell therapy - A method of manipulating allogeneic cells for use in allogeneic cell therapy protocols is described. The method provides a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism called the “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect. The effectiveness and widespread application of the anti-tumor GVT effect is limited by the severe toxicity of the GVH effect. In the present invention, the anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used to stimulate host immunity in a complete HLA mis-matched setting in patients that have not had a prior bone marrow transplant or received chemotherapy and/or radiation conditioning regimens. | 12-23-2010 |
| 20110002959 | Vaccine Production For Pathogenic Bird Viral Diseases - The present invention is an improved method for the production of vaccines to transmittable viral pathogens where the virus is pathogenic to the chicken embryos. Bird embryos are selected for vaccine production from wild and domestic birds, and preferably waterfowl, that have increased resistant to the viral pathogen. The invention is useful for native and engineered viruses. | 01-06-2011 |
| 20110014227 | PRE-OR POST-EXPOSURE TREATMENT FOR FILOVIRUS OR ARENAVIRUS INFECTION - The compositions and methods of the invention described herein provide pre- or post-exposure treatments against filovirus or arenavirus infection by expressing one or more genes (e.g., two ore more genes) from filoviruses or arenaviruses in a delivery vehicle (e.g., a recombinant viral vector or a liposome). | 01-20-2011 |
| 20110014228 | IL23 MODIFIED VIRAL VECTOR FOR RECOMBINANT VACCINES AND TUMOR TREATMENT - The present invention relates to recombinant replicable viral vectors and viruses which are modified with IL23. This IL23 modified virus is highly immunogenic and attenuated for neurotropic pathology found in the wild type viruses. These viruses and vectors can be used for treatment of a variety of cancers and for vaccination against many viral, bacterial, or parasitic diseases. | 01-20-2011 |
| 20110020394 | PCV2 ORF2 VIRUS LIKE PARTICLE WITH FOREIGN AMINO ACID INSERTION - The present invention comprises methods and compositions related to the production and use of amino acid sequences. In particular, PCV2 ORF2 is shown to be useful as a virus-like particle which produces amino acid sequences that retain their immunogenicity or antigenicity when the DNA encoding the PCV2 ORF2 is inserted into an expression system. DNA sequences that are foreign to PCV2 can be attached “in-frame” to the ORF2 DNA and the entire sequence, including the DNA foreign to PCV2, is expressed. It was shown that such sequences retain their antigenicity and therefore their potential utility in immunogenic compositions. | 01-27-2011 |
| 20110020395 | PROBIOTICS FOR USE IN EXPECTING FEMALE MAMMALS FOR ENHANCING THE IMMUNITY OF THEIR OFFSPRINGS - The present invention relates to the use of probiotic on expecting female mammals to boost the immune status of off-spring. The use can induce an enhanced response of the offspring after birth to an infectious antigenic exposure. Ultimately the use of probiotic in expecting females can induce a better protection of offspring against infectious diseases. | 01-27-2011 |
| 20110027310 | Compositions and Methods for Cancer Treatment - Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems. The methods are useful for therapeutically and prophylactically treating cancer such as colon cancer and prostate cancer. | 02-03-2011 |
| 20110027311 | COMBINATION OF PROTEIN VACCINE AND MESENCHYMAL STEM CELLS FOR TREATING CANCER - A method for inhibiting growth and/or metastasis of a tumor in a mammal is disclosed. The method comprises administering to a mammal in need thereof an effective amount of stem cells comprising a transgene encoding at least one oncogenic protein, wherein the stem cells are immortal and show no signs of neoplastic transformation, and administering to the mammal a vaccine composition comprising an effective amount of at least one immunogenic protein capable of eliciting at least one antibody specific against the at least one oncogenic protein, and thereby inhibiting growth and/or metastasis of a tumor in the mammal. A therapeutic kit for inhibiting growth and/or metastasis of a tumor in a mammal is also disclosed. | 02-03-2011 |
| 20110027312 | CHIMERIC PORCINE CIRCOVIRUS PCV2Gen-1Rep AND USES THEREOF - The present invention relates to a novel chimeric nucleic acid molecule of porcine circovirus (PCV2Gen-1Rep) that embraces a nucleic acid molecule encoding porcine circovirus type 2 (PCV2) which contains a nucleic acid sequence encoding a Rep protein of porcine circovirus type 1 (PCV1), particularly wherein the nucleic acid sequence encoding the Rep protein of PCV1 GO is an open reading frame (ORF) gene and, more particularly, wherein the ORF Rep gene is ORF1. A highly desirable chimeric nucleic acid molecule is constructed by replacing the ORF1 Rep gene of PCV2 by the ORF1 Rep gene of PCV1. The invention also encompasses the biologically functional plasmid or viral vector containing the unique chimeric nucleic acid molecules, suitable host cells transfected by the plasmid or vector, infectious chimeric porcine circoviruses that are produced by the suitable host cells, the process for the production of an immunogenic polypeptide product making use of the new chimera, viral vaccines that protect a pig against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2, methods of protecting a pig against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2, methods of preparing the unique chimera of PCV2Gen-1Rep and the like. This invention further includes a new method for improving the replication and titer of PCV2 in a cell culture. | 02-03-2011 |
| 20110033498 | METHODS OF PREVENTING AND TREATING VIRAL INFECTIONS BY INHIBITING THE DelSGYLATION ACTIVITY OF OTU DOMAIN-CONTAINING VIRAL PROTEINS - Viruses having an impaired ability to deISGylate ISG15 conjugates, in particular, viral mutants comprising a mutation in the viral genome that reduces or eliminates the ability of the viral OTU domain-containing protein encoded by the viral genome to deISGylate ISG15 conjugates and/or deubiquitinate ubiquitinated proteins and/or deNeddylate Neddylated proteins are disclosed. Such viral mutants may be used in the formulation of immunogenic compositions for inducing an immune response and preventing, managing and/or treating a viral infection. Also disclosed are methods for identifying anti-viral compounds, in particular, methods of identifying compounds that reduce or inhibit the deISGylation activity and/or deubiquitination and/or deNeddylation activity of a viral OTU domain-containing protein. The compounds identified using such methods may be used as antiviral agents for the prevention, treatment and/or management of viral infections. | 02-10-2011 |
| 20110038890 | Cellular And Viral Inactivation - The invention involves inactivation of viral populations by treating the viral populations with a compound to crosslink proteins in the viral membrane, UV irradiation and further inactivation of the viruses using detergent(s). According to the invention, this method preserves the native structure of viral epitopes so that the inactivated viral preparations can be used in immunological compositions that will inhibit and/or prevent viral infection when administered to an animal. | 02-17-2011 |
| 20110045018 | ASTROVIRUS SPECIES - Provided herein are sequences of the genomes and encoded proteins of new astrovirus species, and variants thereof. Also provided are methods of detecting the new astrovirus species and diagnosing astrovirus infection, methods of treating or preventing astrovirus infection, and methods for identifying anti-astrovirus compounds. | 02-24-2011 |
| 20110045019 | PORCINE TORQUE TENO VIRUS VACCINES AND DIAGNOSIS - The present invention provides four purified preparation containing a polynucleic acid molecule encoding porcine Torque teno virus (PTTV) genotypes or subtypes PTTV1a-VA, PTTV1b-VA, PTTV2b-VA, and PTTV2c-VA. The present invention also provides infectious DNA clones, biologically functional plasmid or viral vector containing the infectious nucleic acid genome molecule of the same. The present invention further provides live, attenuated, vector-expressed and purified recombinant capsid subunit or killed viral vaccines for protection against PTTV infection. The present invention additionally provides subunit vaccines comprising PTTV specific gene products, especially ORF1 capsid gene product for protection against PTTV infection. Further, the present invention provides methods for diagnosing PTTV infection via polymerase chain reaction (PCR) using specific primer for PTTV1, PTTV2, and individual PTTV1 genotypes. Finally, the present invention provides methods for diagnosing PTTV infection via immunological methods, e.g., enzyme-linked immunoabsorbent assay (ELISA) and Western blot using PTTV specific antigens for detecting serum PTTV specific antibodies. | 02-24-2011 |
| 20110052628 | Recombinant Double-Stranded RNA Phage, and Use of the Same - A recombinant double stranded RNA (dsRNA) phage expresses dsRNA-encoded genes in eukaryote cells. Recombinant dsRNA phage are useful for the expression of dsRNA expression cassettes encoding passenger genes, such as, but not restricted to, vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Methods are provided to deliver recombinant dsRNA phage to eukaryotic cells and tissues, either by direct administration, formulated in lipid or polylactide-coglycolide, or by utilizing a bacterial vaccine vector. | 03-03-2011 |
| 20110052629 | METHODS OF REDUCING CONCOMITANT INFECTIONS IN PIGS WITH A PCV2 ANTIGEN - The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. | 03-03-2011 |
| 20110064767 | CDNA CONSTRUCT OF SALMONIDAE ALPHAVIRUS - The invention concerns recombinant DNA's comprising c NDA of genomic RNA of a Salmonidae alphavirus preceded by a spacer sequence, under the control of a suitable promoter. Said recombinant DNA's are useful for obtaining expression vectors, producing recombinant Salmonidae alphavirus, and for obtaining vaccines. | 03-17-2011 |
| 20110091499 | TREATMENT OF PIGS WITH PCV2 ANTIGENT - The present invention relates to a method for the treatment or prophylaxis of a PCV2 infection or for reduction of clinical symptoms caused by or associated with a PCV2 infection in animals a) having anti-PCV2 antibodies and/or b) being young piglets of 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. Preferably, those animals are pigs or young piglets. | 04-21-2011 |
| 20110104201 | Porcine Reproductive and Respiratory Syndrome Vaccine Based on Isolate JA-142 - Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV. | 05-05-2011 |
| 20110110974 | METHODS AND KITS FOR INDUCING A CTL RESPONSE USING A PRIME BOOST REGIMEN - The present invention relates to the generation of a T cell response against a target antigen using a polypeptide comprising a polyepitope construct as a priming composition in a prime boostregimen. | 05-12-2011 |
| 20110110975 | INACTIVATED VIRUS COMPOSITIONS AND METHODS OF PREPARING SUCH COMPOSITIONS - The present invention is a composition comprising a live virus having an infectious component and a plurality of surface antigens in contact with a formaldehyde donor agent having a molecular weight that is less than about 400 g/mol. The present invention further provides a method for deactivating a live virus having an infectious component and a plurality of surface antigens, comprising the steps of: a) providing a live virus having an infectious component and a plurality of surface antigens; and b) contacting the virus with a formaldehyde donor agent having a molecular weight that is greater than about 50 g/mol and less than about 400 g/mol for a period of time (e.g., at least about 12 hours) sufficient for de-activating the infectious component with the formaldehyde donor agent and for preserving at least a portion of the surface antigens to form a deactivated virus. In another embodiment the invention is a method of preparing a composition useful as a vaccine comprising the abovementioned steps in combination with the step of c) mixing a non-toxic effective amount, for inducing an immune response in a subject to which the vaccine is administered, of the deactivated virus with a pharmaceutically acceptable carrier. Preferably the composition containing a pharmaceutically acceptable carrier is useful in, or as, a vaccine composition. | 05-12-2011 |
| 20110110976 | RIFT VALLEY FEVER VIRUS-LIKE PARTICLES AND THEIR USE FOR IMMUNIZATION AND AS TEST SYSTEM - Disclosed is a method for producing virus-like particles (VLP) that comprises the steps of (a) transfecting a mammalian cell line with several independent vectors, including (1) a vector containing at least a substantial part of the M gene from Rift Valley Fever Virus, (2) a vector containing at least a substantial part of the L gene from Rift Valley Fever Virus, (3) a vector containing at least a substantial part of the N gene from Rift Valley Fever Virus and (4) a vector containing a multicloning site flanked by the non-coding 5′- and 3′-ends of the L-, M- or S-segment of Rift Valley Fever Virus, and (b) culturing the transfected mammalian cell line under suitable conditions and obtaining the VLPs from the supernatant of the transfected cultured cell lines. The so-obtained VLPs can be used for vaccination and in methods for testing the antiviral activity of compounds. | 05-12-2011 |
| 20110117125 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS - The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 05-19-2011 |
| 20110123566 | ENDOGENOUS ADJUVANT MOLECULES AND USES THEREOF - Methods of modulating the immune response using pharmaceutical compositions containing crystalline adjuvants are described. In various embodiments the crystalline adjuvants are selected from the group consisting of monosodium urate (MSU), xanthine, basic calcium phosphate (BCP), calcium pyrophosphate dihydrate (CPPD), hydroxyapatite, calcium oxalate, cholesterol, lipid liquid, other crystalline lipids, lithium heparin, talc, and starch. | 05-26-2011 |
| 20110129494 | Vaccine Formulations Comprising Saponin-containing Adjuvants - The present invention provides for a novel oil-in-water (O/W) emulsion, with increased stability in the presence of bacterial or viral suspensions, especially those concentrated and non-purified (crude extracts) or minimally purified. The emulsion of the present invention can act as vehicle for the delivery of a pharmaceutical composition comprising at least one immunogen and, in particular, an immunogen selected from the group consisting of an inactivated pathogen, an attenuated pathogen, a subunit, a recombinant expression vector, and a plasmid or combinations thereof. | 06-02-2011 |
| 20110129495 | TREATMENT OF PRDC IN PIGS - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs. | 06-02-2011 |
| 20110129496 | Use of mTOR Inhibitors to Enhance T Cell Immune Responses - It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog. | 06-02-2011 |
| 20110135684 | Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes in mature dendritic cells in vitro - A method for treating and/or preventing certain ailments by administering to a person in need thereof L-α-lysophosphatidylcholine as an agent for activating the immune system of the person. Also, vaccine compositions that include L-α-lysophosphatidylcholine. | 06-09-2011 |
| 20110150924 | Device, Method, and system for neural modulation as vaccine adjuvant in a vertebrate subject - A method for enhancing an immune response in a vertebrate subject is described. The method includes providing at least one energy stimulus configured to modulate one or more nervous system components of the vertebrate subject, and administering one or more immunogen to the vertebrate subject, wherein the at least one energy stimulus and the one or more immunogen are provided in a combination and in a temporal sequence sufficient to enhance an immune response in the vertebrate subject. | 06-23-2011 |
| 20110159035 | S/O TYPE TRANSDERMAL IMMUNIZING AGENT - It is an objective of the present invention to provide a non-invasive transdermal immunizing technology by which inflammation and lump do not appear at the skin unlike conventional transdermal immunizing methods with subcutaneous administration and the development amount of antibody in serum is increased. The S/O type transdermal immunizing agent according to the present invention comprises an antigen-surfactant complex and an oil phase; wherein the antigen is covered with the surfactant in the complex; the complex is in a solid state; and the complex is dissolved or dispersed in the oil phase. | 06-30-2011 |
| 20110165188 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE - The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof. | 07-07-2011 |
| 20110171254 | CYTOKINE-COATED CELLS AND METHODS OF MODULATING AN IMMUNE RESPONSE TO AN ANTIGEN - The invention relates to a method of vaccinating a mammal to a selected antigen, comprising administering to a mammal a vaccine composition comprising a cytokine-coated cell, wherein the cytokine-coated cell comprises the selected antigen. | 07-14-2011 |
| 20110171255 | EXPRESSION VECTOR ENCODING ALPHAVIRUS REPLICASE AND THE USE THEREOF AS IMMUNOLOGICAL ADJUVANT - The present invention relates to an alphaviral replicase, especially Semliki Forest Virus replicase, or an expression vector encoding an alphaviral replicase, said alphaviral replicase comprising RNA dependent RNA polymerase activity, for use as an immune system modulating adjuvant. The alphaviral replicase may be used in the combination with a vaccine providing an adjuvant function therein, which when present therein will generate an additional boost to the immune response in the subject to whom this combination is administered as compared to when the vaccine alone is administered to a subject in need thereof. The aim of the present invention is to provide an efficient and easy to administer, species-independent adjuvant which will provide advantages to the adjuvants used together with vaccines today. | 07-14-2011 |
| 20110177118 | Non-Simian Cells for Growth of Porcine Reproductive and Respiratory Syndrome (PRRS) Virus - Disclosed are compositions and methods relating to growth of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) using non-simian cells. In a particular example, porcine alveolar macrophage cells are described as having a capability of supporting infectivity and reproduction by PRRSV. Cells and cell lines of the invention are disclosed in connection with applications relating to PRRS disease, including vaccine technologies. | 07-21-2011 |
| 20110182935 | PREVENTION AND TREATMENT OF SUB-CLINICAL PCVD - The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment of sub-clinical PCV2 infection in animals, preferably in pigs. | 07-28-2011 |
| 20110189227 | PORCINE CIRCOVIRUS TYPE 2 AND USE THEREOF - Porcine circovirus type 2 (PCV2) having high replication ability in host cells and use thereof. | 08-04-2011 |
| 20110189228 | Production of Heterologous Polypeptides in Microalgae, Microalgal Extracellular Bodies, Compositions, and Methods of Making and Uses Thereof - The present invention relates to recombinant microalgal cells and their use in heterologous protein production, methods of production of heterologous polypeptides in microalgal extracellular bodies, microalgal extracellular bodies comprising heterologous polypeptides, and compositions comprising the same. | 08-04-2011 |
| 20110189229 | VACCINE AGAINST HPV - The use of HPV 16 and HPV 18 virus like particles (VLPs) together with a pharmaceutically acceptable excipient, in a vaccine for the prevention of human papillomavirus related disease or infection, wherein the vaccine is formulated for administration according to a two dose regimen consisting of a first dose and a second dose. | 08-04-2011 |
| 20110195088 | Porcine Reproductive and Respiratory Syndrome Isolates and Methods of Use - A method of predicting the virulence of a new or uncharacterized PRRS virus strain is provided wherein the strain is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and/or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and/or viremia magnitude of a PRRS virus strain of known virulence, as a measure of the virulence of the new or uncharacterized strain. | 08-11-2011 |
| 20110195089 | COMPOSITIONS, METHODS, AND KITS FOR ENHANCING THE IMMUNOGENICITY OF PATHOGENIC ANTIGENS - The invention provides a method of enhancing the immunogenicity of pathogenic antigens by removing or disrupting intrachain disulfide bonds responsible for maintaining tertiary protein structure. Removal of one or more disulfide bonds can increase the titer of neutralizing antibodies to a pathogen (e.g., a bacterium, fungus, virus, or parasite). The invention also features vaccines, expression vectors, and methods for the manufacture and use thereof. | 08-11-2011 |
| 20110206728 | DNA VACCINES, USES FOR UNPROCESSED ROLLING CIRCLE AMPLIFICATION PRODUCT AND METHODS FOR MAKING THE SAME - A method of eliciting an immune response in an organism comprising: providing an unprocessed rolling circle amplification (RCA) product; and administering an effective amount of the unprocessed RCA product to the organism to elicit the immune response, wherein the unprocessed RCA product is prepared from a circular nucleic acid template comprising at least one promoter sequence, and at least one target sequence. A vaccine comprising unprocessed RCA product is also provided and methods for making the same. | 08-25-2011 |
| 20110206729 | MUCOSAL VACCINE USING CATIONIC NANOGEL - A mucosal vaccine for the prevention or treatment of microbial infections is described that is capable of inducing vaccine antigen-specific immune responses in an organism without the addition of a mucosal adjuvant. The mucosal vaccine comprises a composite of a nanogel comprising a hydrophilic polysaccharide having a cationic functional group and a hydrophobic cholesterol added thereto as a side chain and a vaccine antigen. The vaccine is administered via a mucosal route. | 08-25-2011 |
| 20110212127 | Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine - The invention relates to the preservation of an active agent, such as a polypeptide, by contacting the active agent with a preservation mixture including a sugar and polyethyleneimine. | 09-01-2011 |
| 20110217330 | NOVEL METHOD - The present invention relates to a method for degrading host cell nucleic acids associated with a virus or a viral antigen thereof produced by cell culture, the method comprising at least two steps of nucleic acids degradation with a compound selected from i) an endonuclease and ii) a DNA alkylating agent. | 09-08-2011 |
| 20110229516 | ADJUVANT PHASE INVERSION CONCENTRATED NANOEMULSION COMPOSITIONS - Vaccine adjuvant food nanoemulsion compositions comprising a food safe nonionic surfactant, a hydrophobic food flavorant (e.g., an essential oil), a kosmotrope, and water. The nanoemulsion composition can be used as a vaccine adjuvant composition to enhance inactivated antigens, including protein antigens. Such compositions may be delivered as a nasal or oral spray. The compositions may inherently contain natural antimicrobials and antioxidants and are advantageous over other compositions which often require preservatives, flavorings and antimicrobials. | 09-22-2011 |
| 20110229517 | SYSTEM AND PROCESS FOR PRODUCING MULTI-COMPONENT BIOPHARMACEUTICALS - A sterile, closed, disposable system for formulating biopharmaceutical compositions containing multiple active agents is described herein. | 09-22-2011 |
| 20110250229 | ALLOGENEIC CANCER CELL-BASED IMMUNOTHERAPY - Cell-based immunotherapy (e.g., immunization or vaccination) may be improved by frequent administration to a human subject of allogeneic cancer cells secreting a modified heat shock protein (e.g., gp96), depletion of B cells in the subject, or both. Antigen (e.g., epitope derived from neoantigen or tumor antigen of allogeneic or syngeneic cancer cells) may induce a specific immune response in the subject. For example, the epitope bound in an immunogenic complex with the secreted heat shock protein may be obtained from allogeneic cancer cells coexpressing both secreted gp96 and antigen, or from syngeneic cancer cells of the subject expressing only antigen. | 10-13-2011 |
| 20110250230 | CELL CAPABLE OF EXPRESSING EXOGENOUS GITR LIGAND - Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject. | 10-13-2011 |
| 20110256175 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS - The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 10-20-2011 |
| 20110268761 | Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition - The present invention relates to compositions and methods of treating warts and other human papilloma virus (HPV) skin infections. The present invention relates to compositions and methods of treating skin cancer. | 11-03-2011 |
| 20110280905 | LIVE ATTENUATED CHIMERIC PORCINE CIRCOVIRUS VACCINE - The present invention provides a novel chimeric porcine circovirus infectious DNA clone and live attenuated chimeric virus with the PCV2, preferably of subtype PCV2b, capsid gene integrated into a non-pathogenic PCV1 virus genome. In a particular embodiment, the PCV2 capids gene is of subtype PCV2b, the predominant subtype circulating in pigs worldwide. The attenuated chimeric virus, designated PCV1-2b, effectively protects pigs from PCV2b challenges, and can be used as a live vaccine, as well as an inactivated (killed) vaccine, that provides protection and cross protection against PCV2b and PCV2a subtypes infection. The live attenuated vaccine of the present invention is also effective protecting pigs from porcine circovirus-associated disease (PCVAD). | 11-17-2011 |
| 20110280906 | METHOD FOR AUGMENTING THE IMMUNOGENICITY OF AN ANTIGEN - The present invention relates to a method for augmenting the immunogenicity of an antigen in a mammal, comprising immunizing the mammal with a composition comprising the antigen, and an adjuvant in an amount of effective to augment the immunogenicity of said antigen, wherein the adjuvant comprises a Ling-Zhi-8 (LZ-8) protein. | 11-17-2011 |
| 20110287053 | Recombinant Foot and Mouth Disease Vaccine - A foot and mouth disease virus (FMDV) vaccine and method for producing same is described wherein the N terminal portion of the FMDV polyprotein, encoding the four structural proteins, 1A, 1B, 1C, and 1D, are each separated by a non-FMDV protease, preferably a cellular protease, for example, furin. The expression system may be transformed into a cell expressing the non-FMDV protease and the resulting particles recovered for use as a vaccine | 11-24-2011 |
| 20110293657 | ENCAPSULATED VACCINES FOR THE ORAL VACCINATION AND BOOSTERING OF FISH AND OTHER ANIMALS - The invention relates to a composition comprising a pharmaceutically active agent and a bioadhesive delivery system that provides for the oral delivery of a vaccine to animals, particularly aquatic animals. | 12-01-2011 |
| 20110300177 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF - The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation. | 12-08-2011 |
| 20110300178 | HPV TYPES AND VARIANTS ASSOCIATED WITH CERVICAL CANCER AND THE USES THEREOF - The invention relates to identification of novel sequences associated with cervical cancer, probes and kits for the identification of said sequences, and vaccines suitable for vaccination against new cancer causing HPV types. | 12-08-2011 |
| 20110311581 | REVERSE GENETICS OF NEGATIVE-STRAND RNA VIRUSES IN YEAST - The present invention relates to a methodology for the generation of infectious ribonucleoparticles (RNPs) of negative-strand RNA viruses, and in particular of non-segmented negative-strand RNA viruses in yeast, especially in budding yeast. Accordingly, the patent application relates to a recombinant yeast strain suitable for the rescue of infectious non-segmented negative-strand RNA virus particles or infectious virus-like particles. The invention also relates to the use of the recombinant yeast to prepare vaccine seed and to the use of the produced RNPs or RNPs-like to prepare vaccine formulations. It also concerns the use of the recombinant yeast for the screening of libraries of DNA. | 12-22-2011 |
| 20110311582 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS - The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention formula (I) provides lipids having the following structure XXXIII wherein: R | 12-22-2011 |
| 20110311583 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS - (A1) Translate this text The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure (I) wherein R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ?-aminoalkyls, ?-(substituted)aminoalkyls, ?-phosphoalkyls, ?-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; E is O, S, N(Q), C(O), N(Q)C(O), C(0)N(Q), (Q)N(CO)O, O(CO)N(Q), S(O), NS(O)2N(Q), S(O)2, N(Q)S(O)2, SS, O═N, aryl, heteroaryl, cyclic or heterocycle; and, Q is H, alkyl, ?-aminoalkyl, ?-(substituted)aminoalky, ?-phosphoalkyl or ?-thiophosphoalkyl. | 12-22-2011 |
| 20110311584 | USE OF FLT3 LIGAND FOR ENHANCING IMMUNE RESPONSES IN RNA IMMUNIZATION - The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans). | 12-22-2011 |
| 20110318384 | VECTOR FOR TREATMENT VACCINE FOR STABLE AND CONSTITUTIVE HIGH-EXPRESSION CERVICAL CANCER AND RECOMBINANT LACTOBACILLUS TRANSFORMED BY THE SAME - A surface expression vector for preparing HPV vaccines, in which the surface expression vector contains a gene encoding a repE mutant protein having an amino acid sequence of SEQ ID NO: 1, a promoter, a poly-gamma-glutamate synthetase complex gene, and a gene which is linked with the poly-gamma-glutamate synthetase complex gene and encodes a tumor induction-associated antigen protein of human papillomavirus. | 12-29-2011 |
| 20120027796 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS - The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures: (Formula (I) or (XXXV)). | 02-02-2012 |
| 20120027797 | Preservation of Bioactive Materials by Freeze Dried Foam - This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes. | 02-02-2012 |
| 20120034263 | SEQUENCES DIAGNOSTIC FOR SHRIMP PATHOGENS - Primers have been isolated that are diagnostic for the detection of the white spot syndrome virus (WSSV). The primers are based on a new portion of the WSSV genome and may be used in primer directed amplification or nucleic acid hybridization assay methods. | 02-09-2012 |
| 20120058144 | LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS - The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures XIV or XVII. | 03-08-2012 |
| 20120076819 | Compositions And Methods For Treating of Microbial Infections - The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions. | 03-29-2012 |
| 20120093855 | RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF - The present invention relates to the field of isolation of enveloped virus-based virus-like particles (VLPs) free of infectious agents. In preferred examples, the field includes methods of inactivation of infectious agents that do not adversely affect the immunogenicity of the enveloped virus-based VLPs. In certain embodiments, the enveloped virus-based VLPs are produced in insect cell based expression systems. | 04-19-2012 |
| 20120093856 | METHODS FOR USING EXTRACELLULAR ADENOSINE INHIBITORS AND ADENOSINE RECEPTOR INHIBITORS TO ENHANCE IMMUNE RESPONSE AND INFLAMMATION - A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction. | 04-19-2012 |
| 20120100179 | USE OF MICRORNAS TO CONTROL VIRUS HELPER NUCLEIC ACIDS - Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided. | 04-26-2012 |
| 20120100180 | METHODS FOR PROLIFERATION OF ANTIGEN-SPECIFIC T CELLS - Methods for expansion of antigen-specific T cells are provided. Said methods include following steps: generating antigen-specific T cells by stimulation of T cells with antigen A; introducing genes encoding immune recognition molecule specific to major histocompatibility complex (MHC) molecule bound with a peptide derived from antigen B into the antigen A specific T cell to produce bi-specific T cells recognizing both target cells expressing antigen A peptide associated MHC and target cells expressing antigen B peptide associated MHC; stimulating the bi-specific T cells by antigen A for expansion of the bi-specific T cells in vitro or in vivo. Methods of the present invention can be applied to expand various of T cells with specific to cancer cells with tumor antigen peptide loaded MHC molecules for adoptive therapy against unmet medical need such as tumors etc. | 04-26-2012 |
| 20120107350 | VIRUS-LIKE PARTICLES OF CAPSID PROTEINS FROM HUMAN PAPILLOMAVIRUS TYPE 16/58/18/6/11 AND THE METHOD FOR PREPARATION AND THE USES THEREOF - Five optimized genes of capsid L1 protein from human papillomavirus type 16, 58, 18, 6 and 11, which are modified by using insect's preferred codons and so on. Method for modifying those genes to express more highly in insect cells. Virus-like particle's vaccine compositions comprising HPV L1 proteins or their functional relatives produced by using those modified genes. Those optimized genes of L1 can be used to produce HPV 16 VLP, HPV 58VLP, HPV 18VLP, HPV 6 VLP, HPV 11VLP in insect cells. Yields of virus-like particles derived from those optimized HPV L1 genes are high. Mixed multivalent vaccines comprising above optimized HPV L1 genes can be used to prevent and treat multiple HPV infection and diseases related with it. | 05-03-2012 |
| 20120107351 | In Ovo Vaccination of Campylobacter in Avian Species - The present invention provides a method of inducing an immune response against | 05-03-2012 |
| 20120107352 | LIPOPOLYSACCHARIDE OF OCHROBACTRUM INTERMEDIUM AND THEIR USE AS IMMUNOSTIMULANT OF MAMMALIANS - The present invention relates to the isolation, purification and characterization of the Lipopolysaccharide (LPS) from | 05-03-2012 |
| 20120107353 | COMPOSITION - The invention relates to a composition comprising at least one ISCOM complex and at least one internal antigen which is not a surface antigen and not in the form of a part of a whole micro-organism. The internal antigen may be a nucleoprotein or presented as a member of the group of components obtained after disintegrating a micro-organism. The ISCOM complex may be an ISCOM or ISCOM matrix complex. The composition may also comprise non internal antigens. The invention also elates to the composition for use as an immune stimulating medicine or vaccine, especially for use in eliciting T cell respond including CTL respond. The invention also relate to a composition comprising at least one ISCOM complex for use as an immune stimulating or immune modulating medicine or vaccine for the stimulation of dendritic ceils in elderly. Further, the invention relates to a process for preparing a composition wherein a saponin, cholesterol and a lipid are mixed with a lysed cell suspension of cells and solubilising agent without removal of any cell components, where after the solubilising agent is removed or diluted. It also relates to a kit. | 05-03-2012 |
| 20120128715 | METHOD FOR STIMULATING THE IMMUNE RESPONSE OF NEWBORNS - The present invention is based on the surprising discovery that agonists of TLR8 are uniquely efficacious in enhancing (e.g. inducing) the immune response of newborns. Thus, agonists of TLR8 serve as both vaccine adjuvants and as adjunctive therapies for acute infection in newborns, preferably the agonist is a TLR8-selective agonist. The immune response induced, or enhanced, in the neonatal host can be, for example, a cytokine immune response and/or a humoral immune response (e.g., antigen-specific). | 05-24-2012 |
| 20120156239 | OPTIMIZED VACCINES TO PROVIDE PROTECTION AGAINST EBOLA AND OTHER VIRUSES - The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same. | 06-21-2012 |
| 20120156240 | METHODS FOR PREPARING VESICLES AND FORMULATIONS PRODUCED THEREFROM - The present disclosure provides methods for preparing vesicles. In some embodiments, the methods involve providing a molten mixture of vesicle forming lipids and then adding the molten mixture to an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. In other embodiments, the methods involve providing a lyophilized lipid product and rehydrating the lyophilized lipid product with an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. The lyophilized lipid product is prepared by melting vesicle-forming lipids to produce a molten lipid mixture and then lyophilizing the molten lipid mixture. The present disclosure also provides antigen-containing vesicle formulations prepared using these methods. The present disclosure also provides kits that include a lyophilized lipid product in a first container and an aqueous solution comprising an antigen in a second container. | 06-21-2012 |
| 20120164171 | Antiviral Activity of Bovine Type III Interferon Against Foot-and-Mouth Disease Virus - Interferons are the first line of defense against viral infections and administration of interferons as biotherapeutics has been demonstrated to be effective in controlling several viral infections. Here we report for the first time the identification and characterization of a member of the bovine type III IFN family, boIFN-λ3. We have expressed boIFN-λ3 using a recombinant replication defective human adenovirus type 5 (Ad5) and demonstrated antiviral activity against foot-and-mouth disease virus (FMDV) and vesicular stomatitis virus (VSV) in bovine cells in vitro. Furthermore, we have tested the efficacy of boIFN-λ3 against FMDV in vivo by inoculation of cattle with Ad5-boIFN-λ3 followed by intradermolingual or aerosol virus challenge. Our results demonstrate that the type III IFN family is conserved in bovines and that treatment of cattle with boIFN-λ3 alone or in combination with IFN-α is able to confer delayed and reduced severity of FMD. Furthermore inoculation with Ad5-boIFN-λ3 alone conferred full protection against aerosol challenge for at least 7 days after administration suggesting that type III IFN used in combination with FMD vaccines could fill one of the current gaps in emergency vaccination against FMDV. | 06-28-2012 |
| 20120164172 | Cancer Therapy - An agent that stimulates antiviral immunity may be used, for the treatment of cancer. A product comprising an immunostimulant and a vector comprising a transgene that promotes death of neoplastic cells, may also be used for simultaneous, sequential or separate administration in the treatment of cancer. | 06-28-2012 |
| 20120164173 | Papilloma Pseudovirus and Preparation - The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body. | 06-28-2012 |
| 20120177683 | METHODS FOR PREPARING VESICLES AND FORMULATIONS PRODUCED THEREFROM - The present disclosure provides methods for preparing vesicles. In general, these methods include steps of providing a lyophilized lipid product and rehydrating the lyophilized lipid product with an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. The lyophilized lipid product is prepared by dissolving vesicle-forming lipids in a polar-protic water-miscible organic solvent to produce a lipid solution and then lyophilizing the lipid solution. The present disclosure also provides antigen-containing vesicle formulations prepared using these methods. The present disclosure also provides kits that include a lyophilized lipid product in a first container and an aqueous solution comprising an antigen in a second container. | 07-12-2012 |
| 20120177684 | PAPILLOMAVIRUS VACCINE COMPOSITIONS - The present invention relates to pharmaceutical compositions comprising virus-like particles (VLPs) of HPV, said VLPs adsorbed to an aluminum adjuvant, and an ISCOM-type adjuvant comprising a saponin, cholesterol, and a phospholipid. In preferred embodiments, the aluminum adjuvant comprises amorphous aluminum hydroxyphosphate sulfate. Another aspect of the invention provides multi-dose HPV vaccine formulations comprising HPV VLPs and an antimicrobial preservative selected from the group consisting of: m-cresol, phenol and benzyl alcohol. Also provided are methods of using the disclosed pharmaceutical compositions and formulations to induce an immune response against HPV in a human patient and to prevent HPV infection. | 07-12-2012 |
| 20120183575 | EXOSOME BASED TREATMENT OF CANCER - A method of treating cancer in a patient comprises immortalizing B cells collected from the patient by infection with Epstein Barr virus, transforming the cells to a latent stage, culturing the cells in the presence of a cancer antigen, harvesting exosomes released from the cells, administering the exosomes to the patient. Alternatively the harvested exosomes are loaded with cancer antigen. | 07-19-2012 |
| 20120189655 | Attenuated Live Vaccine for Prevention of Porcine Reproductive and Respiratory Syndrome - The present disclosure provides an attenuated live vaccine strain and the formulations thereof, for preventing pigs from infection of porcine reproductive and respiratory syndrome (PRRS). The preparation methods for the vaccines and the formulations are also provided. The attenuated live vaccine strain provided herein offers significant immunological protection to pigs against PRRS. The vaccine formulations of the present disclosure also have advantages in long shelf lives as well as good stability during storage. | 07-26-2012 |
| 20120189656 | REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS - Expression of a transgene is driven in a host cell using a pol I promoter which is not endogenous to an organism from the same taxonomic order from which the host cell is derived. | 07-26-2012 |
| 20120195925 | Vaccines with increased immunogenicity and methods for obtaining them - Vaccines with increased immunogenicity, distinct in that in the capacity of a specific immunogenic component, whole vaccine antigens or vaccine antigens that have been cut into oligomer fragments are used; the mixture (assembly) of oligomer fragments or whole antigen obtained is modified by changing its molecular charge to the opposite. | 08-02-2012 |
| 20120195926 | METHODS OF IMPROVING VACCINE IMMUNOGENICITY - The present invention provides a process called “Immune Banking” that enhances vaccine efficacy by exploiting existing humoral responses. The process involves tagging new antigens with molecular markers recognized by an existing anti-body response. This recognition of the tagged vaccine components enhances adaptive immune responses to the new vaccine. | 08-02-2012 |
| 20120201849 | VACCINE STABILIZER - Disclosed herein is a formulation capable of enhancing thermostability and shelf-life of a biological product, the formulation comprising: a tertiary amine N-oxide or a derivative thereof represented by the formulae: | 08-09-2012 |
| 20120244181 | CREATING BIOENGINEERED LYMPH NODES - The invention provides compositions and methods of treating various conditions, including tumors, with compositions comprising dendritic cells expressing exogenous chemokines. | 09-27-2012 |
| 20120258133 | Construct - The present invention provides a construct which, when expressed in a host cell, is capable of producing empty virus capsids, the construct comprising: (i) a nucleotide sequence encoding a capsid precursor protein; (ii) a nucleotide sequence encoding a protease capable of cleaving the capsid precursor protein; and (iii) a control element which controls the expression of the protease such that, when the construct is present in the host cell, the control element causes the protease to be expressed at a level sufficient to cleave the capsid precursor protein, but not sufficient to induce significant toxicity in the host cell. The invention also provides a vector and a host cell comprising such a construct and their use to generate empty virus capsids. | 10-11-2012 |
| 20120263753 | BENZONAPHTHYRIDINE-CONTAINING VACCINES - The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) polymeric particles and (c) a benzonaphthyridine compound, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides, inter alia, methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits. | 10-18-2012 |
| 20120263754 | Methods for Enhancing Immunogen Specific Immune Responses by Vectored Vaccines - Provided herein are methods for inducing a specific immune response in a subject by administering to the subject an immunogenic composition comprising a recombinant expression vector, or a vector particle comprising the recombinant expression vector, which vector comprises a polynucleotide sequence that encodes an immunogen of interest. The methods further comprise administering an adjuvant composition either concurrently or sequentially with the immunogenic composition. | 10-18-2012 |
| 20120269849 | ATTENUATED INFLUENZA VIRUSES AND VACCINES - The present provides attenuated influenza viruses comprising a modified viral genome containing a plurality of nucleotide substitutions. The nucleotide substitutions result in the rearrangement of preexisting codons of one or more protein encoding sequences and changes in codon pair bias. Substitutions of non-synonymous and synonymous codons may also be included. The attenuated influenza viruses enable production of improved vaccines and are used to elicit protective immune responses. | 10-25-2012 |
| 20120269850 | Method of Inducing an Immune Response - A method is provided for inducing or enhancing an immune response in a mammal to a target polypeptide expressed in a plurality of cells of the mammal, which method comprises administering to the mammal an inhibitory nucleic acid which targets a region of a ribonucleic acid (RNA) which encodes said polypeptide. Also provided is a pharmaceutical composition comprising an inhibitory nucleic acid which targets a region of an RNA which encodes a target polypeptide expressed in a plurality of cells of a mammal, such that translation of an aberrant form of the target polypeptide occurs in said cells, said truncated form of the target polypeptide comprising one or more T cell epitopes; together with a pharmaceutically acceptable carrier or diluent. | 10-25-2012 |
| 20120315294 | Needle-free administration of PRRSV vaccines - The invention provides novel methods and compositions for the vaccination of porcine animals against porcine reproductive and respiratory syndrome virus (PRRSV). Described herein are immunological and/or vaccine compositions comprising a DNA vector encoding a PRRSV protein, particularly a truncated ORF7 protein, which are administered to porcines using needle-free delivery. The plasmid can include more than one nucleic acid molecule such that the plasmid can express more than one antigen. Also disclosed are methods for using and kits employing such compositions. | 12-13-2012 |
| 20120321664 | MODULATION OF YEAST-BASED IMMUNOTHERAPY PRODUCTS AND RESPONSES - Disclosed are methods to modulate yeast-based immunotherapy products and the immune responses, prophylactic responses, and/or therapeutic responses elicited by such products. Also disclosed are modified yeast-based immunotherapy products, kits and compositions. | 12-20-2012 |
| 20130011434 | ADJUVANT DILUENTS FOR LIVE VACCINES FOR PIG DISEASES - A method for preparing an injectable vaccine composition intended to combat porcine reproductive and respiratory syndrome (PRRS), includes at least the step in which: a) a live vaccine is mixed extemporaneously with an adjuvant diluent (AD). The adjuvant diluent is an oil-in-water-type emulsion or an oil-in-water-type microemulsion, or an aqueous solution including water and at least one inorganic salt selected from aluminum hydroxide, cerium nitrate, zinc sulfate, colloidal iron hydroxide or calcium chloride, salts of divalent or trivalent metals or sympathomimetic compounds. | 01-10-2013 |
| 20130028931 | NOVEL PRRS VIRUS INDUCING TYPE I INTERFERON IN SUSCEPTIBLE CELLS - The present invention relates to the field of attenuated live viruses useful as vaccine or medicament for preventing or treating Porcine Reproductive and Respiratory Syndrome (PRRS) in swine, and is based on the surprising finding of a PRRS virus which is able to induce the interferon type I response of a cell infected by said virus. In one embodiment, the PRRS virus according to the invention is a PRRS virus mutant comprising, in comparison with the genome of a wild type strain, a mutation in the gene encoding the non structural protein 1 (nsp1) of said virus. | 01-31-2013 |
| 20130028932 | COMPOSITIONS COMPRISING POLYGLUTAMIC ACID NANOPARTICLES AND POLYPEPTIDES SUCH AS CD40 AGONISTS - The present invention provides pharmaceutical compositions comprising an immunostimulatory polypeptide and polyglutamic acid (PGA) nanoparticles, formulated in a pharmaceutically acceptable diluent, carrier or excipient. Such compositions have utility in stimulating the immune system in subjects, with the components capable of interacting synergistically. The invention further provides uses of the compositions of the invention, for example in the treatment of cancer, and kit and components for use in the same. | 01-31-2013 |
| 20130039942 | Compositions and Methods for Self-Adjuvanting Vaccines against Microbes and Tumors - The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immuno stimulator intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracelluar signaling peptide must be present in a complex of three or more units in order to stimulate an immune response. Inserting this fusion construct into viruses like HIV-1 or introducing it into dendritic cells or tumor cells is predicted to lead to a positive therapeutic effect in humans, non-human mammals, birds, and fish. | 02-14-2013 |
| 20130039943 | NOVEL METHOD - A method for inactivating an orthomyxovirus propagated in cell culture and/or inactivating contaminating adventitious agents, comprising at least the following steps:
| 02-14-2013 |
| 20130052219 | PREPARATION METHOD OF VIRUS EXPRESSING ALPHA-GALACTOSE EPITOPE AND VACCINE - A method for producing an α-Gal-expressing virus having enhanced immune response to viruses, without requiring the use of any enzyme; an influenza virus vaccine having a high effect (antigenicity), which is produced using an α-Gal-expressing virus produced by the method; and others. Specifically disclosed are: a method for producing an α-galactose epitope (Galα1-3Galβ1-4GlcNAc-R: α-Gal hereinafter)-expressing virus, which comprises the steps of: (1) introducing an α1,3- galactosyltransferase gene in an expressible condition into a cell line that does not express α-Gal to obtain a cell line capable of expressing α-Gal; | 02-28-2013 |
| 20130058972 | METHODS FOR REGULATING COMPLEMENT CASCADE PROTEINS USING ASTROVIRUS COAT PROTEIN AND DERIVATIVES THEREOF - The present invention provides a method for modulating the complement cascade by depleting the plasma of the functional activity of complement proteins and thereby reducing or eliminating complement-mediated cell lysis. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated cell lysis and peptide mediators of inflammation. The invention provides a method for the therapeutic use of coat proteins and derivatives thereof from the Astroviradae family of viruses in the treatment of complement-mediated diseases. Methods are described herein where complement cascade, triggered by either the classical or alternative complement pathways, is prevented from effecting cell lysis and inflammation due to inhibition or depletion of one or more complement components in the serum following administration of astrovirus coat proteins or derivatives. | 03-07-2013 |
| 20130064849 | METHODS TO TREAT AND PREVENT CARDIOVASCULAR DISEASE USING HUMAN PAPILLOMAVIRUS VACCINES - Embodiments of the invention include methods of treating or preventing cardiovascular disease, including atherosclerosis, myocardial infarction, and stroke, by administering an HPV vaccine, particular a vaccine that induces immunity against an oncogenic HPV type such as types 16 and 18. | 03-14-2013 |
| 20130071429 | BUNYAVIRUS VACCINE - The present invention provides attenuated viruses for use as vaccines and for the treatment and/or prevention of viral diseases and/or infections. | 03-21-2013 |
| 20130071430 | MICRORNA-CONTROLLED RECOMBINANT VACCINIA VIRUS AND USE THEREOF - It is intended to provide a vaccinia virus that specifically proliferates in a cancer cell and destroys the cancer cell and to provide use of the virus in cancer treatment. The present invention provides a microRNA-controlled vaccinia virus, in which a target sequence of a microRNA less expressed in a cancer cell than in a normal cell is inserted in a 3′ untranslated region of B5R gene associated with viral proliferation in a vaccinia virus, wherein the microRNA-controlled vaccinia virus specifically proliferates in the cancer cell and has an oncolytic property that destroys the cancer cell. | 03-21-2013 |
| 20130071431 | Method for Preserving Polypeptides Using A Sugar and Polyethyleneimine - The invention relates to the preservation of an active agent, such as a polypeptide, by contacting the active agent with a preservation mixture including a sugar and polyethyleneimine. | 03-21-2013 |
| 20130078275 | NOVEL SYSTEMS, VECTORS, AND METHODS FOR DELIVERY OF BIOMOLECULES TO EUKARYOTIC CELLS - Embodiments described herein provide novel bacterial-based methods, systems, and delivery vehicles capable of delivering DNA, RNA, proteins, and other cargo into targeted mammalian cells, both in vitro and in vivo, with high efficiency. Delivery vehicles may be used to deliver molecules such as prophylactic or therapeutic proteins, DNA, shRNA, DNA vaccines, mucosal vaccines, modified viruses or viral components, and other bioactive molecules. Potential applications include gene therapy, wound healing therapies, cancer therapy, immune modulation, and research applications for which delivery of DNA, RNA, proteins, or other cargo into mammalian cells and tissues is required. | 03-28-2013 |
| 20130108663 | ENHANCING THE T-CELL STIMULATORY CAPACITY OF HUMAN ANTIGEN PRESENTING CELLS IN VITRO AND IN VIVO AND THEIR USE IN VACCINATION | 05-02-2013 |
| 20130115243 | IMMUNOGENIC FORMULATIONS AND THEIR USES - An immunogenic formulation for a patient, the formulation includes virus-modulated hematopoietic cancer cells, where the modulated hematopoietic cancer cells are generated from viable hematopoietic cancer cells obtained from the patient, either isolated or in a mixed hematopoietic population of healthy and cancer cells, and where the viable hematopoietic cancer cells are infected ex vivo with a virus that modulates the expression of a plurality of endogenous immune regulatory molecules to increase the immunogenicity of the hematopoietic cancer cells. | 05-09-2013 |
| 20130122042 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF - The present invention generally relates to compositions comprising benzonapthyridine small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject that has had pre- or post-exposure to a pathogen such as hemorrhagic fever virus. Also provided are methods of preparing and using the SMIP compositions of the invention. | 05-16-2013 |
| 20130122043 | MODIFIED POLYPEPTIDES AND PROTEINS AND USES THEREOF - The present invention provides modified multi-chain and multi-subunit proteins and methods for making them. In some protease embodiments the proteins are modified AB | 05-16-2013 |
| 20130122044 | NOVEL INTERFERON-ALPHA-PRODUCING BONE MARROW DENDRITIC CELLS - A novel dendritic cell type has been identified within bone marrow, termed myelos interferon dendritic cells (miDC). These novel cells possess the high IFN-alpha producing activity of pDC, but they also display a wide TLR responsiveness along with T-cell stimulation capacities that more closely resemble the conventional DC populations. Moreover, these cells appear less prone to apoptosis upon activation stimuli, including viruses. These cells constitute a novel bone marrow innate immune cell type, ideally geared to linking innate and adaptive immune responses via their potent IFN-alpha production and high cell stimulatory capacity. | 05-16-2013 |
| 20130149335 | PROTEIN FORMULATIONS - The invention relates to the discovery that the addition of aromatic carboxylate ions inhibit protein instability caused by aromatic preservatives. Thus, the invention relates to compositions, (preferably aqueous compositions, comprising a protein, an aromatic preservative and aromatic carboxylate ions. The proteins remain stable and suitable for storage at ambient temperatures or lower, even in aqueous form. Preferably, the aqueous composition comprises a protein, a phenolic preservative and benzoate ions, wherein the pH of the composition is at least 1 unit greater than the pK | 06-13-2013 |
| 20130149336 | Methods for Screening Viral Like Particles and Identifying Neutralizing Epitopes and Related Vaccines, Constructs, and Libraries - The invention is directed to methods of screening immunogenic viral like particles and related immunogenic compositions and diagnostic techniques. In one embodiment, the invention provides methods of screening immunogenic viral like particles containing peptides corresponding to epitope regions of a wide variety of pathogens, including viruses, bacteria, parasites, and microbes. Non-infectious antigens and allergens of interest can also be screened as described herein. Immunization, therapeutic and diagnostic applications are also described for the compositions and methods according to the invention. | 06-13-2013 |
| 20130171191 | Compositions and Methods for Enhancing Dendritic Cell Resistance to Bacterial Infection and for Enhancing the Mobility of Dendritic Cells for Dendritic Cell-Based Immunotherapy - Compositions and methods comprising dendritic cells expressing elevated levels of fascin 1 useful in immunotherapy are disclosed. | 07-04-2013 |
| 20130177590 | N-HYDROXYAMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE - The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions thereof and methods of use thereof relating to the treatment of cancer and other diseases. | 07-11-2013 |
| 20130189301 | Ablative immunotherapy - The disclosure herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues. The immunotherapy relates to first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing in situ necrosis or apoptosis in a tumor or pathogen infected lesion. Necrosis or apoptosis can be induced by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue. One or more doses of allogeneic cells (e.g., Th1 cells) are then delivered within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen. | 07-25-2013 |
| 20130189302 | IMMUNOTHERAPEUTIC METHOD USING ARTIFICIAL ADJUVANT VECTOR CELLS THAT CO-EXPRESS CD1D AND TARGET ANTIGEN - Provided is immunotherapy of cancer or infection utilizing activation of dendritic cell (DC) by innate immunity, namely, a method of preparing an artificial adjuvant vector cell co-expressing a target antigen and CD1d and having an ability to activate immunity against the target antigen, comprising treating the target antigen and CD1d co-expressing cell with a CD1d ligand in a culture medium. | 07-25-2013 |
| 20130209508 | Compositions Containing Purine and Pyrimidine Nucleotsides, Peptides, and Manganese and Their Uses - The invention provides methods of producing vaccines directed against microorganisms, with the methods comprising culturing, harvesting and/or suspending the microorganism in the presence of a radiation-protective composition and irradiating the bacteria or viruses with a dose of radiation sufficient to render the microorganism replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide. The invention also provides methods of rendering bacteria in culture resistant to ionizing radiation (IR), with these methods comprising culturing the bacteria in the presence of a radiation-protective composition. | 08-15-2013 |
| 20130236493 | METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES - The invention relates to methods of producing infectious bunyavirus replicon particles. These bunyavirus replicon particles are safe and can be used outside a biosafety containment. The invention further relates to recombinant bunyavirus replicon particles and uses of these recombinant bunyavirus replicon particles. | 09-12-2013 |
| 20130243815 | INHIBITORS OF DSRNA-DEPENDENT PROTEIN KINASE (PKR) AS ENHANCERS OF BUNYAVIRUS LIVE-ATTENUATED VACCINES - Certain embodiments of the invention are directed to methods and compositions for inhibiting dsRNA-dependent protein kinase (PKR) and augmenting the immunogenicity of Bunyavirus live-attenuated vaccines. | 09-19-2013 |
| 20130273102 | PARENTERAL NOROVIRUS VACCINE FORMULATIONS - The present invention relates to single dose parenteral vaccine compositions comprising mixtures of monovalent Norovirus virus-like particles. Methods of conferring protective immunity against Norovirus infections in a human subject by administering such compositions are also disclosed. | 10-17-2013 |
| 20130280295 | ALUMINUM COMPOUNDS FOR USE IN THERAPEUTICS AND VACCINES - The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition. | 10-24-2013 |
| 20130302370 | REDUCTION OF CONCOMITANT INFECTIONS IN PIGS BY THE USE OF PCV2 ANTIGEN - The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. | 11-14-2013 |
| 20130315952 | ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC INFECTION - The invention provides compositions and methods for the prophylaxis or treatment of diseases or disorders in a subject (e.g., a mammal, such as a human) including, e.g., diseases or disorders caused by biological agents, autoimmune diseases, and cancer. The compositions include a delivery vector (e.g., a viral vector, such as an Ad5 vector) encoding an interferon (e.g., IFN-α), and are provided to the subject by, e.g., intranasal or pulmonary administration. | 11-28-2013 |
| 20130323277 | SCHMALLENBERG VIRUS (SBV) VACCINE, METHODS OF PRODUCTION, AND USES THEREOF - The present invention relates to the field of vaccines and medicaments for the prophylaxis and treatment of infectious diseases in ruminants. In particular, it relates to inactivated Schmallenberg virus (SBV) useful as vaccine or medicament for preventing or treating viremia, the transmission and clinical symptoms, in particular malformations in newborn ruminants such as cattle, sheep and goats, induced by SBV. | 12-05-2013 |
| 20130337008 | ADENOVIRAL VECTOR-BASED DENGUE FEVER VACCINE - The invention relates to a replication-deficient adenoviral vector comprising two or more nucleic acid sequences encoding Dengue virus antigens and a chimeric hexon protein. The chimeric hexon protein comprises a first portion and a second portion. The first portion comprises at least 10 contiguous amino acid residues from a first adenovirus serotype (e.g., serotype 5 adenovirus hexon protein), optionally with one amino acid substitution. The second portion comprises (a) at least one hypervariable region (HVR) of a hexon protein of an adenovirus of a second adenovirus serotype, or (b) at least one synthetic hypervariable region (HVR) that is not present in the hexon protein of the wild-type adenovirus of the first adenovirus serotype. | 12-19-2013 |
| 20130344105 | METHOD FOR AUGMENTING THE IMMUNOGENICITY OF AN ANTIGEN - The present invention relates to a method for augmenting the immunogenicity of an antigen in a mammal, comprising immunizing the mammal with a composition comprising the antigen, and an adjuvant in an amount of effective to augment the immunogenicity of said antigen, wherein the adjuvant comprises a Ling-Zhi-8 (LZ-8) protein. | 12-26-2013 |
| 20140004145 | PURIFICATION OF VIRUS LIKE PARTICLES | 01-02-2014 |
| 20140004146 | METHOD FOR PRODUCING VIRUS-LIKE PARTICLE BY USING DROSOPHILA CELL AND APPLICATIONS THEREOF | 01-02-2014 |
| 20140017278 | ADENOVIRUS SEROTYPE 26 AND SEROTYPE 35 FILOVIRUS VACCINES - Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection. | 01-16-2014 |
| 20140044750 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION - The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family, including Ebola and Marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds include phosphorodiamidate morpholino oligonucleotides (PMOplus) having a nuclease resistant backbone, about 15-40 nucleotide bases, at least two but typically no more than half piperazine-containing intersubunit linkages, and a targeting sequence that is targeted against the AUG start site region of Ebola virus VP35, Ebola virus VP24, Marburg virus VP24, or Marburg virus NP, including combinations and mixtures thereof. | 02-13-2014 |
| 20140050760 | Replication-Defective Arenavirus Vectors - The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III. The modified arenaviruses are useful as vaccines and therapeutic agents for a variety of diseases. | 02-20-2014 |
| 20140056939 | ENHANCING THE T-CELL STIMULATORY CAPACITY OF HUMAN ANTIGEN PRESENTING CELLS IN VITRO AND IN VIVO AND ITS USE IN VACCINATION - We provide new methods of in vitro or in vivo enhancing the T-cell stimulatory capacity of human DCs and the use thereof in cancer vaccination. The method includes the introduction of different molecular adjuvants to human DCs by contacting or modifying them with mRNA or DNA molecule(s) encoding CD40L, and CD70 or constitutively active TLR4 (caTLR4). | 02-27-2014 |
| 20140079734 | Methods and Compositions for Alphavirus Replicons - The present invention provides alphavirus replicons and methods of their use in producing heterologous protein. | 03-20-2014 |
| 20140086952 | Vaccine Adjuvants from Self-Assembling Peptides - Pharmaceutical or veterinary compositions, vaccine systems, methods, and kits for treating or protecting a subject from a condition using peptide-based adjuvants are provided. The peptide adjuvants comprise a peptide having a hydrophobic region, a turning region, and a hydrophilic region. The turning region comprises amino acid residues GSII (SEQ ID NO: 10). The peptide adjuvants can be used to immunopotentiate active agents by improving the immune response to the active agent. | 03-27-2014 |
| 20140120136 | MIR-155 ENHANCEMENT OF CD8+ T CELL IMMUNITY - The present invention provides novel methods of enhancing CD8+ T cell mediated immunity (also referred to as “CD8+ T cell immunity”) in a patient having a diseased state. In particular, the present invention provides for the enhanced expression of miR-155 in a population of patient specific T cells through the introduction of a nucleic acid molecule encoding a miR-155 transcript or a nucleic acid molecule encoding a chimeric antigen receptor and a miR-155 transcript into those cells, followed by the reintroduction of the T cells into the patient. The present invention also provides methods of enhancing the expansion of these T cells relative to control cells. Increased expansion of CD8+ T cells following enhanced miR-155 expression is directly related to enhanced CD8+ T cell immunity. The present invention further provides methods of enhancing anti-cancer immunity in a patient through the increased expression of miR-155 in patient specific T cells. | 05-01-2014 |
| 20140127260 | HPV VACCINE FORMULATIONS COMPRISING ALUMINUM ADJUVANT AND METHODS OF PRODUCING SAME - The invention provides human papillomavirus (HPV) antigen formulations which show increased antigen stability. More specifically, the invention provides stable HPV formulations comprising HPV virus-like particles (VLPs) bound to an aluminum salt adjuvant and further comprise a combination of sucrose and mannitol. The vaccine formulations of the invention are stable following freeze-thaw and freeze-drying. Also provided are lyophilized and frozen HPV vaccine formulations comprising HPV VLPs of at least one HPV type adsorbed onto an aluminum salt adjuvant, sucrose, and mannitol. Methods of making the stable vaccine formulations of the invention are also provided. | 05-08-2014 |
| 20140134206 | INFLAMMATION AND IMMUNITY TREATMENTS - Therapeutic use of extracts containing proanthocyanidin including treating disorders, e.g., inflammatory disorders, e.g., inflammatory bowel disease, Crohn's disease, ulcerative colitis, indeterminate colitis, microscopic colitis, collagenous colitis, and irritable bowel syndrome. Methods of increasing a subject's immunological resistance to an infection and/or treating the infection. The infection can be, e.g., a bacterial, viral, or fungal infection. The methods can include, e.g., selecting a subject that has, or is at risk of developing, an infection, e.g., a bacterial, viral, or fungal infection, or a combination thereof; providing a composition comprising at least about 10% proanthocyanidin by weight; and administering to the subj ect an amount of the composition to the subject, to thereby increase a subject's immunological resistance to an infection and/or to treat the infection. | 05-15-2014 |
| 20140134207 | RECOMBINANT RIFT VALLEY FEVER (RVF) VIRUSES AND METHODS OF USE - Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus. | 05-15-2014 |
| 20140154288 | PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR STIMULATION OF THE INNATE IMMUNE RESPONSE - The use of compositions comprising a papaya mosaic virus (PapMV) moiety for stimulation of the innate immune response is provided. The PapMV moiety may be papaya mosaic virus or PapMV virus-like particles (VLPs). The PapMV compositions stimulate a sufficiently strong innate immune response to provide protection against subsequent pathogen challenge or to treat an established infection. The use of PapMV compositions to protect a subject from potential infection by a pathogen, such as a viral pathogen, a bacterial pathogen or a fungal pathogen, and the use of PapMV compositions to treat an established infection, are also provided. The PapMV compositions be administered, for example, via intranasal or pulmonary routes to elicit effects within the mucosa and/or in the respiratory system. | 06-05-2014 |
| 20140161837 | VACCINE ADJUVANT, VACCINE COMPOSITION AND METHOD FOR PREPARING A VACCINE ADJUVANT - The disclosure provides a vaccine adjuvant, including a polysaccharide derived from | 06-12-2014 |
| 20140186395 | PERMISSIVE CELLS AND USES THEREOF - Described are methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Further described are methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular, for PRRSV. Methods of utilzing the cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of the virus for the purpose of vaccine production or diagnosis, are also described. | 07-03-2014 |
| 20140193457 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES - The present invention relates to immunostimulatory oligodeoxynucleotides, vectors and vaccines comprising such oligodeoxynucleotides, to their use as a medicament, to their use in preventing or combating infectious disease and to methods for the detection of such oligodeoxynucleotides. | 07-10-2014 |
| 20140205632 | DOWN REGULATION OF THE GENE EXPRESSION BY MEANS OF NUCLEIC ACID-LOADED VIRUS-LIKE PARTICLES - The present invention relates to compositions of virus-like particles for the introduction of RNA-interference (RNAi-) inducing molecules into eukaryotic cells and methods for the cell type-specific transduction of a plurality of eukaryotic cells with RNAi-inducing molecules. The present invention furthermore relates to methods for a diagnosis, prevention and/or treatment of diseases or disease states associated with an increased expression rate of at least one endogenous gene, and/or with the undesired expression of at least one endogenous gene and/or foreign nucleic acids, in particular viral nucleic acids. | 07-24-2014 |
| 20140220074 | Toll-Like Receptor 4 (Tlr-4) Agonist Peptides For Modulating Tlr-4 Mediated Immune Response - Peptides including an amino acid sequence of a fragment of mammalian Toll-like receptor-4 (TLR-4), analogs and derivatives thereof, and pharmaceutical compositions including these peptides. Methods for modulating a TLR-4 mediated immune response, particularly stimulating TLR-4 mediated immune response, thereby treating infectious diseases and cancer. | 08-07-2014 |
| 20140248310 | CATIONIC METAL OXIDES FOR USE AS VACCINE ADJUVANTS - Adjuvant and immunological vaccine compositions comprising modified, cationic metal oxides are disclosed, including methods of making modified, cationic metal oxides and methods of using the modified metal oxides in vaccine formulations and regimens. | 09-04-2014 |
| 20140255444 | COMPOSITIONS AND METHODS FOR TREATING EBOLA VIRUS INFECTION - The compositions and methods of the invention described herein provide treatments against Ebola virus infection by expressing gene(s) from the Ivory Coast ebolavirus (ICEBOV) species in a recombinant viral vector. | 09-11-2014 |
| 20140308312 | USE OF MICRORNAS TO CONTROL VIRUS HELPER NUCLEIC ACIDS - Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided. | 10-16-2014 |
| 20140314807 | Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof - The present invention relates to compositions comprising replication defective Schmallenberg virus vaccines, methods of producing the vaccines, and the administration of such vaccines to animals, including ovines and bovines. The invention further relates to methods for providing long-term protective immunity against Schmallenberg in animals, including ovines and bovines. | 10-23-2014 |
| 20140314808 | INFECTIOUS CDNA CLONE OF EUROPEAN PRRS VIRUS AND USES THEREOF - The present invention belongs to the field of animal health and relates to a nucleic acid sequence which comprises the genome of an infectious genotype I (EU) PRRS virus clone useful for studying Porcine Reproductive and Respiratory Syndrome (PRRS), a viral disease affecting swine, and in the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of PRRS. | 10-23-2014 |
| 20140328874 | SAMPLE QUANTIFICATION BY DISC CENTRIFUGATION - To overcome the limitations of existing particle quantification techniques, the inventors used disc centrifugation in combination with a detector, to quantify particles, in particular virus particles. Also provided is a method for determining particle density using a disc centrifuge. This method is particularly useful for determining virus particle density. Also provided is a method of estimating particle size, based on particle density. | 11-06-2014 |
| 20140348874 | METHOD FOR THE REDUCTION OF PCV-2 IN A HERD OF SWINE - The present invention relates to a PCV2 ORF2 protein for use in a method for the reduction of the viral load, for the reduction of the infection quota and/or the reduction of the infection pressure in a herd of swine caused by an infection with PCV2. In particular, the present invention relates to any method described above, wherein said PCV2 ORF2 protein is to be administered at regular intervals to female animals of a herd and to piglets. | 11-27-2014 |
| 20150010593 | METHODS AND CELLS FOR THE PRODUCTION OF VIRAL VACCINES - The present invention provides genetically modified cells useful for viral replication and the production of viral vaccines. | 01-08-2015 |
| 20150056248 | PORCINE CIRCOVIRUS TYPE 2 (PCV2) SUBUNIT VACCINE - Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of a different subtype, the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of a different subtype, or the prevention or treatment of a disease caused by an infection with PCV2 of a different subtype. | 02-26-2015 |
| 20150125488 | METHODS AND COMPOSITIONS INVOLVING IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES - Described is an immunostimulatory oligodeoxynucleic acid molecule (ODN) having the structure according to formula (I), wherein any NMP is a 2′ deoxynucleoside monophosphate or monothiophosphate, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, -6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine-monophosphate or -monothiophosphate, NUC is a 2′ deoxynucleoside, selected from the group consisting of deoxyadenosine-, deoxyguanosine-, deoxyinosine-, deoxycytosine-, deoxyuridine-, deoxythymidine-, 2-methyl-deoxyinosine-, 5-methyl-deoxycytosine-, deoxypseudouridine-, deoxyribosepurine-, 2-amino-deoxyribosepurine-, 6-S-deoxyguanine-, 2-dimethyl-deoxyguanosine- or N-isopentenyl-deoxyadenosine, any X is O or S, a and b are integers from 0 to 100 with the proviso that a+b is between 4 and 150, B and E are common groups for 5′ or 3′ ends of nucleic acid molecules, as well as a pharmaceutical composition containing such ODNs. | 05-07-2015 |
| 20150297706 | Particulate Vaccine Formulations for Inducing Innate and Adaptive Immunity - Disclosed are compositions, kits, and methods for inducing an immune response against an infection or a disease. The compositions typically include biodegradable particles having an average effective diameter of 0.5-20 μm, and optionally the compositions include one or more of an adjuvant, an apoptosis inhibitor, and an antigen. The compositions, kits, and methods may be utilized to induce a cell-mediated response, such as a T-helper cell response, and/or a humoral response against a pathogen or a disease. In some embodiments, the compositions, kits, and methods may be utilized to induce preferentially a Th1 response versus other types of immune responses such as a Th2 response. | 10-22-2015 |
| 20150297707 | MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine, | 10-22-2015 |
| 20150297708 | MULTIVALENT PCV2 IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS - An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine. | 10-22-2015 |
| 20150374774 | PICRORHIZA EXTRACT FOR PREVENTION, ELIMINATION AND TREATMENT OF INFECTION DISEASES - An anti-viral composition comprising terpenes and fatty acids found in the Scophulariaceae family of plants is disclosed. It further comprises other lipophillic constituents and the aglycons of the glycosides occurring in said family of plants. Preferably, the composition is derived by extraction of the roots and rhizomes of mixtures of | 12-31-2015 |
| 20160002608 | METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES - The invention relates to methods of producing infectious bunyavirus replicon particles. These bunyavirus replicon particles are safe and can be used outside a biosafety containment. The invention further relates to recombinant bunyavirus replicon particles and uses of these recombinant bunyavirus replicon particles. | 01-07-2016 |
| 20160008454 | COMPOSITIONS AND METHODS FOR TREATMENT OF MICROBIAL INFECTIONS | 01-14-2016 |
| 20160008488 | Vectors And Methods For Genetic Immunization | 01-14-2016 |
| 20160024476 | ANTI-MYCOBACTERIAL VACCINES - Provided herein are genetically modified arenaviruses suitable as vaccines against mycobacterial infections. The invention also relates to pharmaceutical compositions and methods for the prevention and treatment of mycobacterial infections. Specifically, provided herein are pharmaceutical compositions, vaccines, and methods of preventing and treating infections in | 01-28-2016 |
| 20160040136 | NOVEL PRRS VIRUS INDUCING TYPE I INTERFERON IN SUSCEPTIBLE CELLS - The present invention relates to the field of attenuated live viruses useful as vaccine or medicament for preventing or treating Porcine Reproductive and Respiratory Syndrome (PRRS) in swine, and is based on the surprising finding of a PRRS virus which is able to induce the interferon type I response of a cell infected by said virus. In one embodiment, the PRRS virus according to the invention is a PRRS virus mutant comprising, in comparison with the genome of a wild type strain, a mutation in the gene encoding the non structural protein 1 (nsp1) of said virus. | 02-11-2016 |
| 20160076005 | NOVEL KOREAN-TYPE PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) VIRUS - The present invention relates to a Korean-type porcine reproductive and respiratory syndrome virus (PRRSV) and a vaccine composition using the same, and a method for preventing porcine reproductive and respiratory syndrome. Korean-type porcine reproductive and respiratory syndrome virus with accession number KCTC 12096BP according to the present invention is Korean-type porcine reproductive and respiratory syndrome virus distinguished from European strains and North American strains, and a vaccine composition specific to Korean-type porcine reproductive and respiratory syndrome virus is produced, thereby preventing a Korean-type porcine reproductive and respiratory syndrome virus or specifically diagnosing the infection with Korean-type porcine reproductive and respiratory syndrome virus. | 03-17-2016 |
| 20160095924 | AMINO LIPIDS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS - The present invention provides superior compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of specific target proteins at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 04-07-2016 |
| 20160114023 | CANCER AND SKIN LESION TREATMENT - A method for treating or reducing the incidence of recurrence of cancer, benign tumors or HPV-associated lesions, including skin cancer, and particularly squamous cell carcinoma (SCC and basal-cell carcinoma, by administering one or more doses of HPV recombinant vaccine to a patient. | 04-28-2016 |
| 20160137595 | IDO INHIBITORS - There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention. | 05-19-2016 |
| 20160143870 | IDO INHIBITORS - There are disclosed compounds of Formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention. | 05-26-2016 |
| 20160144018 | METHODS OF PREPARING ANTI-HUMAN PAPILLOMAVIRUS ANTIGEN T CELLS - Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed. | 05-26-2016 |
| 20160144037 | ADJUVANT COMPOSITIONS AND RELATED METHODS - The present disclosure provides for an adjuvant composition that is suited for injectable as well as transdermal administration. The adjuvant composition generally comprises a lipophile, a polymer of acrylic or methacrylic acid, saline, cholesterol, a saponin, and sodium hydroxide. A vaccine composition is also provided for that generally includes the vaccine composition of the present disclosure and an antigen. A method for vaccinating animals and humans utilizing the adjuvant composition of the present disclosure is also provided. | 05-26-2016 |
| 20160151483 | BETA-GLYCOLIPIDS FOR USE AS ADJUVANTS | 06-02-2016 |
| 20160166682 | Treatment of Infection | 06-16-2016 |
| 20160184426 | Toll-Like Receptor 4 (Tlr-4) Agonist Peptides For Modulating Tlr-4 Mediated Immune Response - Peptides including an amino acid sequence of a fragment of mammalian Toll-like receptor-4 (TLR-4), analogs and derivatives thereof, and pharmaceutical compositions including these peptides. Methods for modulating a TLR-4 mediated immune response, particularly stimulating TLR-4 mediated immune response, thereby treating infectious diseases and cancer. | 06-30-2016 |
| 20160195531 | CORRELATION OF DISEASE ACTIVITY WITH CLONAL EXPANSIONS OF HUMAN PAPILLOMAVIRUS 16-SPECIFIC CD8+ T-CELLS IN PATIENTS WITH SEVERE EROSIVE ORAL LICHEN PLANUS | 07-07-2016 |
| 20160250317 | SCHMALLENBERG VIRUS (SBV) VACCINE, METHODS OF PRODUCTION, AND USES THEREOF | 09-01-2016 |
